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Since the Greek physician Galen had associated of an imbalance in "black bile" with cancer, to 
the post-mortem observation of tumor-like cells in the blood by Thomas Ashworth in 1869, 
and to the validation of circulating tumor cells (CTCs) as a prognostic tool in the early 2000's, 
the scientific community has always demonstrated an ever-deepening interest in these rare 
cells and their role in the metastatic process 1,2. CTCs are exceedingly rare cells found into 
whole blood of cancer patients. They have the potential to serve as a 'blood biopsy', enabling 
population-wide screening for early diagnosis, highly sensitive prognostic monitoring for 
cancer patients, and serial non-invasive molecular profiling to bring the science of 
personalized medicine to practical fruition in the clinic. Furthermore, while much has been 
hypothesized about their potential role in the hematogenous dissemination of cancer, the 
biological characterization of these cells could lead to an entirely new class of therapies 
targeting metastasis. Metastasis is the spread and growth of tumor cells from the primary site 
to distant organs, is conceivably the most devastating and deadly attribute of cancer, and is 
ultimately responsible for more than 90% of cancer-related deaths, resulting in over 500,000 
deaths each year in the United States alone. Circulating tumor cells have the potential to be 
highly informative concerning our understanding of metastasis. Present technologies, 
however, enable only a subset of potential analyses to be conducted, principally due to sub-
optimal cell isolation sensitivity, purity, throughput, or handling method [details in Appendix 
1].  
 
F IGURE 1 MODEL OF TUMOR PROGRESSION 3 
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Origin of CTCs 
Ten years ago, I.J. Fidler  postulated that a primary tumor composed by 109 tumor cells can 
sheds millions of tumor cells into circulation every days, but the development of lung 
metastases was very rare in an experiment where 2x106 cancer cells were injected into 
rabbits4.  
These findings lead to consider the cancer cells spreading as an inefficient process where only 
a little percentage of circulating tumor cells could generate metastases. What happens to the 
vast majority of the tumor cells that fail to form metastases is still matter of debate since the 
metastatic process consists of a long series of sequential, interrelated steps.  . Each of these 
can be relate limiting, as a failure or an insufficiency at any of the steps can stop the entire 
process. The outcome of the process is dependent on both the intrinsic properties of the 
tumour cells and the responses of the host.  
The very first step of metastatic dissemination is thought to include the detachment of 
epithelial cells from the extracellular matrix (ECM) and the disruption of the actin skeleton, 
leading to cells rounding.  Both of these events normally trigger apoptotic process, which 
termed anoikis and amorphosis respectively.  
The ability to survive in the absence of normal matrix components represents a  crucial 
property of metastatic cells, as tumor cells that intravasate into the circulation and 
extravasate into secondary tissue sites are either deprived of matrix or exposed to foreign 
matrix components 5,6. 
To enter the bloodstream a tumor cell has to negotiate and survive the process of 
intravasation. A fluorescence-based in vivo study using orthotopically injected metastatic 
versus non-metastatic tumor cells showed that a large number of the non-metastatic cells 
fragment when interacting with blood vessels, whereas the metastatic cells display increased 
survival during this process 7, indicating that the entry of cancer cells into the vasculature 
constitutes an important barrier to metastasis.  
The efficiency of metastasis inhibition by apoptosis induction in the early phases of entrance 
into the circulation and extravasation is probably another important regulatory mechanism 
that counteracts metastasis development. Cell death might occur as a result of two main 
effects: cell destruction by mechanical stress and cell death mediated by the immune system.  
Furthermore, to form metastases circulating cancer cells have to pass through several stressful 
and highly selective steps, including arrest in the capillary bed and resumption of proliferation 
in distant organs.  
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TUMOR PROGRESSION MODELS:  L INEAR VS  PARALLEL  
The debate about metastases development and consequently the role of CTCs is still open: on 
one hand there is the linear progression model and on the other the parallel progression 
model. 
The linear progression model is based on Leslie Fould’s description of a stepwise progression 
of morphological abnormalities 8 accompanying cancer [Figure 2].  
Accumulation of genetic and epigenetic alterations was subsequently associated with this 
process 9. At its simplest, the model states that cancer cells pass through multiple successive 
rounds of mutation and selection for competitive fitness 10 in the context of the primary 
tumor. After a significant number of such rounds the cells may be able to proliferate relatively 
autonomously at a competitive rate. These tumor cell clones expand and individual cancer 
cells leave the primary site to seed secondary growths. 
The final clonal expansion of fully malignant clones is linked to tumor size. For example, 
mutations of the tumor suppressor gene TP53 are rare in T1 stage (<2 cm; sizes refer to 
diameter throughout) breast cancers, and significantly more frequent in T3 stage (>5 cm) 
tumors 11  
 
F IGURE 2 TUMOR LINEAR PROGRESSION 12 
Such observations and the well-known association of tumor size with higher frequency of 
metastasis, which is the basis of the routinely used TNM classification system, have promoted 
the concept that only tumor cells that are shed late in primary tumor progression have the 
possibility of eventually spawning macroscopic metastases 13. 
However, the possibility that dissemination of tumor cells occurs early (when tumors are 
small), after acquisition of fully malignant traits, cannot be excluded. Such cells, having 
departed early, are also thought to share most of their characteristics with the primary tumor. 
The parallel progression model dates back at least to the 1950s 14, when considerable effort 
was made to quantify human cancer growth rates. These studies concluded that metastasis 
must be initiated long before the first symptoms appeared or the primary tumor was 
diagnosed 14,15; given their growth rates, metastases were simply too large to be accounted 
for by initiation at a late stage of primary tumor development [Figure 3]. 




F IGURE 3 TUMOR PARALLEL PROGRESSION 12 
Parallel progression does not necessarily place metastatic founder cell dissemination near the 
end of primary tumor development. On the contrary, dissemination of tumor cells that are 
still evolving may lead to allopatric selection and expansion of variant cells adapted to specific 
microenvironments 14 .  
Owing to selection pressure and the inherent genetic instability of tumor cells, parallel 
progression predicts greater disparity between metastatic founder and primary tumor cells 
than does linear progression and emphasizes the mechanistic importance of site-specific 
selection of genetic and epigenetic alterations. Finally, the parallel progression model makes 
three testable predictions. The first is parallel and independent accumulation of genetic and 
epigenetic alterations in the primary tumor compared with the metastasis. The second is 
seeding of tumor cells to different distant sites in parallel, independent, niche-related 
adaptation during outgrowth towards metastasis. The third is parallel ontogenesis of 
metastatic cells that disseminated from the primary site at different times. Because, in parallel 
progression, metastatic founder cells in most cases disseminate long before clinically 
detectable disease, there is ample time for multiple waves of dissemination or continuous 
spread. 
Both models of tumor progression consider the emergence of multiple metastases. In parallel 
progression, metastatic founder cells are selected in parallel at various sites and grow 
independently. Linear progression predicts metastasis from metastasis, in part predicated on 
the assumption that a metastasis is at least as able to spawn metastases as is the primary 
tumor, as it has been selected to do so. This view emerged from autopsy studies and selection 
of highly metastatic cell lines in vivo 16. The autopsy studies were taken to support linear 
progression from primary tumors to metastatic cascades. However, growth rates and therapy 
     5 
 
trials argue against a linear progression from first to secondary metastasis.  For example, the 
median time taken for 50% of breast cancer patients to develop a single metastasis after 
diagnosis of M0 disease and surgery is shortest for the liver, taking 29 months. However, the 
median time taken for M0 stage patients to be diagnosed with multiple metastases, including 
liver (such as liver and lung or liver and brain), after surgery is 28 months 17.  
Parallel progression diminishes the emphasis on metastatic cascades in favor of direct (and 
early) seeding from the primary lesion. Favored metastatic sites may thus reflect the 
probability and rate of specific tumor cells growing in a given niche. In counter- point to this, 
the prognostic value of circulating tumor cells (CTCs) in the blood of patients with metastasis 
may be considered as support for metastatic cascades. 
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Epithelial to Mesenchymal Transition 
Changes in cell phenotype between epithelial and mesenchymal states, defined as epithelial–
mesenchymal (EMT) [Figure 4] and mesenchymal–epithelial (MET) transitions, have key roles 
in embryonic development an wound healing processes, and their importance in the 
pathogenesis of cancer and other human diseases is increasingly recognized 18–21. 
 
F IGURE 4 EMT  HALLMARKS IN DEDIFFERENTIATED TUMOR  THE PRIMARY 22. TUMOUR AND METASTASES SHOW THE SAME 
HETEROGENEITY,  WITH A TUBULAR DIFFERENTIATED PHENOTYPE IN THE CENTER AND AN UNDIFFERENTIATED PHENOTYPE AT THE 
PERIPHERY.  THIS IS  ALSO INDICATED SCHEMATICALLY (A DIFFERENTIATED PHENOTYPE IS INDICATED WITH BLUE AND AN 
UNDIFFERENTIATED PHENOTYPE IS INDICATED WITH PURPLE). A  SMALL DIFFERENTIATED METASTASIS WITH ADJACENT SINGLE,  
UNDIFFERENTIATED TUM OUR CELLS IS SHOWN (BOTTOM PANEL). 
However, even though developmental and pathological EMT forms have many common 
features, they also have obvious differences, leading to the classification of three different 
EMT types 23 [Figure 5]. Type 1 refers to developmental EMTs; type 2 denotes those related 
to wound healing, tissue regeneration, and organ fibrosis; and type 3 indicates the EMT 
associated with cancer. Developmental EMTs imply the conversion of epithelial into 
mesenchymal cells, but embryos lack inflammatory responses, typical of type 2 and 3 EMTs 
that occur in the adult 23,24. Type 2 EMTs are also characterized by the appearance of 
myofibroblasts with the ability to secrete an excess of extracellular matrix molecules in 
response to inflammation 23. In contrast to the situation in embryos, in cancer cells and during 
regeneration, the acquisition of a mesenchymal state in fibrosis can be considered an end 
stage, which leads to organ degeneration and failure. During cancer progression, tumor cells 
undergo type 3 EMT, which, in addition to invasion and motility, involves intravasation of 
delaminated cells into lymphatic and blood vessels and their subsequent extravasation. 
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F IGURE 5 DIFFERENT EMT TYPES 23 TYPE 1 EMT  IS ASSOCIATED WITH IMPLANTATION AND EMBRYONIC GASTRULATION AND GIVES 
RISE TO THE MESODERM AND ENDODERM AND TO MOBILE NEURAL CREST CELLS.  THE PRIMITIVE EPITHEL IUM,  SPECIFICALLY THE 
EPIBLAST,  GIVES RISE TO PRIMAR Y MESENCHYME VIA AN EMT. EMTS ARE RE-ENGAGED IN THE CONTEXT OF INFLAMMATION AND 
FIBROSIS AND REPRESENT THE TYPE 2 EMTS. UNLIKE THE TYPE 1  EMT,  THE TYPE 2  EMT IS  EXPRESSED OVER EXTENDED PERIODS OF 
TIME AND CAN EVENTUALLY DESTROY AN AFFEC TED ORGAN IF THE PRIMARY INFLAMMATORY INSULT IS NOT REMOVED OR ATTENUATED. 
F INALLY,  THE SECONDARY EPITHELIA ASSOCIATED WITH MANY ORGANS CAN TRANSFORM INTO CANCER CELLS THAT LATER UNDERGO 
THE EMTS THAT ENABLE INVASION AND METASTASIS, THEREBY REPRESENTING TYPE 3 EMTS 
Another essential difference between the embryonic and tumorigenic processes is that the 
tumorigenic processes involve genetically abnormal cells that progressively lose their 
responsiveness to normal growth-regulatory signals and possess the ability to evolve. Such 
evolution derives from the genetic and epigenetic instability that is inherent in most neoplastic 
cell types.  
The hallmarks of the EMT can be summarized as follows: loss of cell-cell junctions, loss of 
apico-basal polarity, and acquisition of migratory and invasive properties 25.  
Epithelial cells form layers kept together by specialized membrane structures (tight junctions, 
adherens junctions, desmosomes and gap junctions). The organization of these junctions as a 
lateral belt, the localized distribution of adhesion molecules such as cadherins and some 
integrins, the polarized organization of the actin cytoskeleton, and the presence of a basal 
lamina used as substratum define the characteristic ‘‘top–bottom’’ apico-basal polarity of 
epithelial cells. 
In contrast, mesenchymal cells interact with their neighbours only at focal contacts without 
forming organized cell layers, and do not have an apico-basal polarized actin cytoskeleton. 
Instead, mesenchymal cells are elongated and motile in a three-dimensional space defining a 
front–back polarity with a leading edge enriched in integrins and matrix metalloproteinases 
(MMP). EMT describes the process in which epithelial cells lose their epithelial characteristics, 
gain mesenchymal features, and become motile 
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Recently it has become clear that EMT is driven by at least four fundamental regulatory 
networks, which are closely interrelated, and modulation of any of these networks affects the 
others. The most extensively studied network is undoubtedly the network of  the nuclear 
factors (described below). There is growing evidence that three additional layers of regulation 
support the EMT programme: the expression of small non- coding RNAs 26, differential splicing 
27,28, and translational and post-translational control (which affect protein stabilization and 
localization). 
EMT is controlled by at least five major signalling pathways [Figure 6] that are used in early 
embryonic development (the WNT, TGFb, Hedgehog, Notch and receptor tyrosine kinase 
pathways) 29,30. These pathways are often disregulated in cancer 31–35 , and they often 
cooperate to drive EMT 36,37. 
 
F IGURE 6 THE MOLECULAR NETWORK OF KNOWN SIGNALING PATHWAYS AND TRANSCRIPTION FACTORS THAT REGULATE THE 
EPITHELIAL-MESENCHYMAL TRANSITION PROGRAM IN CARCINOMA CELLS 21 
There are many examples where induction of EMT in cultured tumor cells results in increased 
metastatic potential in animal models 29. The transcriptional programs activated by TGF- 38,39, 
PDGF 40 and NFKB, in vitro 36 have also been detected in vivo in animal models and in human 
tumor samples 40–43. 
TGF-, for example, induces EMT in H-Ras-transformed mammary epithelial cells, a process 
that has recently shown to be dependent on NF-kB 44. Importantly, inhibition of NF-kB activity 
caused a reversal of EMT and also abrogated the metastatic potential of the tumour cells in 
vivo, providing further evidence for a link between EMT and metastasis. Snail family genes 
have also been implicated in tumour-associated EMT and metastasis, and constitute tumour 
progression markers that can be expressed at the invasive front of tumours 45 
Alongside to pathways implicated in EMT, specific markers have been identified, trying to 
distinguish between epithelial and mesenchymal cells, which often play key functional roles 29 
An example is E-cadherin, a transmembrane protein localized to the adherens junctions and 
basolateral membrane that plays a central role in organizing the cell–cell adhesion complexes 
typical of epithelial cells 46. It is expressed in epithelial cells but not in mesenchymal cells, and 
is generally down-regulated during EMT. 
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Due to the pivotal role of E-cadherin loss, EMT-TFs are sometimes referred to as E-cadherin 
repressors; also, a decrease in functional E-cadherin is often associated with the activation of 
EMT. However, it is important to bear in mind that the EMT program and EMT-TFs are much 
more than E-cadherin transcriptional repressors, that E-cadherin down-regulation (or 
endocytosis) is not necessarily associated with the EMT program, and that E-cadherin re-
expression is not sufficient to revert the fibroblastic phenotype 47 
On the other hand, mesenchymal cells express intermediate filaments, such as vimentin, 
specific cadherins such as N-cadherin and OB-cadherin, cytosketletal proteins, including 
smooth muscle actin, c-actin, - filamin and talin, and extracellular matrix components, such 
as fibronectin and collagen precursors, as well as specific integrins and MMPs 
The ability of the transcription factor SNAI1 to directly repress E-cadherin has been considered 
dogma since its initial observation 48,49, and this conviction has been reinforced over the years. 
The list of potent EMT-inducing transcription factors (EMT-TFs) has been growing ever since 
50, revealing regulatory networks that are often described as signalling pathways converting 
stimuli to transcriptional reprogramming 20,51. 
EMT-TFs have been involved not only in migration and invasion but also in the suppression of 
senescence and apoptosis, attenuation of cell-cycle progression and resistance to 
radiotherapy and chemotherapy 25,52,53. 
For an epithelial cell to undergo a full EMT, the cell should be permissive: the mesenchymal 
end-stage can be considered the ultimate goal and will only be achieved when necessary 
component pathways of the network are activated. There is good evidence to support the 
idea that dedifferentiation is triggered if the balance between different regulatory networks 
is fundamentally disturbed; this probably requires the disruption of more than one layer. 
A recent study by Rhim and colleagues further supports the concept of permissiveness, using 
a model of pancreatic cancer in which yellow fluorescent protein (YFP)-labelled pancreatic 
epithelial cells have a mutant K-RAS combined with loss of Trp53 54 [Figure 7]. 
 
F IGURA 7  L INEAGE-LABELED MOUSE MODELS OF PANCREATIC CANCER AND DETECTION OF EMT 54 TIME COURSE OF MALIGNANT 
PROGRESSION IN PKCY  MICE.  (D–F)  REPRESENTATIVE IMAGES  OF MALIGNANT PROGRESSION.  PRIOR TO WEANING,  PKCY  MICE HAVE 
HISTOLOGICALLY NORMAL PANCREATA (D)  BUT DEVELOP PANIN  LESIONS (E)  AND EVENTUALLY PDAC  (F).  (G–I)  IMAGES OF 
PANCREATA FROM (D)–(F)  STAINED WITH AN ANTIBODY AGAINST YFP  (GREEN)  AND N-CADHERIN (N-CAD,  RED);  PRIOR TO WEANING,  
SCANT N-CAD STAINING IS  SEEN (G).  (J  AND K)  FLUORESCENT IMAGES OF LINEAGE-LABELED CELLS DERIVED FROM THE PANCREATIC 
EPITHELIUM . 
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On the one hand, induction of EMT at an early stage is sufficient for the cells (that is, 
permissive cells) to escape the primary lesions, supporting the possibility of parallel tumour 
progression. On the other hand, 42% of the YFP-positive cells in these tumours had undergone 
EMT, supporting the existence and potency of EMT during primary tumour progression. In 
fact, all of these in vivo studies provided a better understanding of why EMT downstream of 
an EMT-TF is much easier to detect in vitro: cell lines are genetically aberrant, resulting in 
different degrees of plasticity and allowing a range from partial to full EMT to occur. 
While it is clear that EMT-like processes are not an obligate for invasion and metastasis, there 
is nevertheless compelling evidence that these processes can play an important role in 
determining the dissemination of tumours. 
This is consistent with the concept of “migratory cancer stem cells” 55 also and provides a link 
between the EMT program and the characteristics associated with cancer stem cells (CSCs), 
that is self-renewal, proliferation rate decrease, drug resistance and the capacity to seed 
secondary tumors and produce differentiated non-stem cells 56. Recent evidence suggests that 
cells that undergo EMT acquire stem cell-like properties (Figure 6A). These undifferentiated 
mesenchymal cells are characterized by a shift from E- to N-cadherin expression, the 
expression of Snail factors, vimentin, and metalloproteases.  
However, the link between EMT and stemness is another controversial issue in tumorigenesis, 
as it was later shown that fibroblasts must undergo a MET to complete the initial 
reprogramming of fibroblasts to iPSCs 57,58. Again, help may come from studies on 
development biology 59–61, although CSCs differ from canonical embryonic stem cells (ESCs) in 
that they revert to the phenotypes of only the primary tumor and, therefore, have a more 
restricted potency than ESCs and iPSCs 62. 
Circulating cancer stem cells  
The concept that tumor cells within a primary tumor are heterogeneous in terms of their 
metastatic and renewal potential is not a recent one. Studies done more than 50 years ago 
demonstrated that only some tumors could be grown from a single tumor cell, and that the 
daughter cells could be morphologically different from the parent 63. This work laid the 
foundation for the modern cancer stem cell hypothesis, which posits that within tumors there 
exists a subset of cells that are capable of continuous self-renewal and that can give rise to 
differentiated progeny 62. 
The discovery of cancer stem cells (CSCs) has stimulated great excitement, as well as heated 
debates, for both stem cell and cancer biologists. How the CSC theory fits into the general 
scheme of cancer progression, particularly with respect to metastasis, has not been 
completely defined. In order to sustain a lifelong supply of blood cells, hematopoietic stem 
cells (HSCs) must have the ability to self-renew and generate differentiated blood cells. With 
the landmark work accomplished by John Dick and his co-workers in human leukemia studies, 
the existence of CSCs has now been established in many solid tumors including those arising 
in the brain 64,65, colon 66–70, breast 71–73, skin 74,75, prostate 76, and pancreas 77,78. 
Similar to normal stem cells, CSCs can reproduce themselves through the process of self-
renewal, which can be studied in serial transplantation assays. Additionally, cancers derived 
from purified CSCs recapitulate the heterogeneous phenotypes of the parental cancer from 
which they were derived, reflecting the differentiation capacity of CSCs 79,80 . 
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The origin of these cells remains unclear; are they derived from normal stem cells with a 
cancerous phenotype? Or do previously differentiated progenitor cells with oncogenic 
mutations regain the ability to self-renew? A third theory hypothesizes that CSCs may come 
from a rare fusion event between stem cells and other cells. Normal stem cells may be ideal 
target cells for accumulating mutations that are necessary for stepwise malignant 
transformation due to their inherent self-renewal capacity. Since multiple pathways are 
involved in self-renewal of stem cells, it seems conceptually more difficult for a differentiated 
cell to regain this ability through mutations. But the rareness of stem cells in tissues may 
counter this theory because of the low probability that they could be targeted by mutations. 
The relative abundance of transient amplifying immediate progenitor cells, derived from stem 
cells retaining partial self-renewal capacity, makes them likely candidates for initial 
transforming events. 
Kang et al proposed a CSC-based model for both tumorigenesis and metastasis, in which either 
adult stem cells, their more differentiated progenies or fused cells, could be subject to initial 
transforming events. Gain of self-renewal capacity at early phases of cancer is essential for 
further accumulation of oncogenic transformations and eventual development of cancer. The 
genetic and/or epigenetic changes could determine the cancer malignancy, metastatic 
potential and the tissue tropism upon the CSC pool establishment. The initial origin of CSCs 
may influence the phenotypes of developing cancer, including the metastatic property. 
Molecular crosstalk between the primary tumor and the pre-metastasis niche through 
secreted stimulatory signals helps govern the homing of metastatic CSCs. 
Like in embryogenesis, metastatic stem cells tropism towards preferred tissues and organs is 
guided by cues such as oxygen gradients or other chemo-attractants derived from niche sites 
81–84. 
It is increasingly clear that the cell heterogeneity characteristic of many cancer types results 
from a hierarchical organization that resembles that of the tissue of origin (Figure 8). CSCs 
comprise the apex of this hierarchy and appear to be the phenotypic and functional 
equivalents of normal stem cells harboring oncogenic mutations. CSCs in primary tumors self-
renew their own population and can generate short-lived progeny. 
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F IGURE 8 SOURCES,  DISSEMINATION,  DORMANCY,  AND OUTGROWTH OF METASTATIC STEM CELLS  85  SEVERAL TYPES OF CANCER 
DISPLAY A HIERARCHICAL ORGANIZATION WITH CSCS BEING THE ONLY CELL TYPE WITH LONG-TERM SELF-RENEWAL POTENTIAL ..  CSCS 
INTERACT WITH MICRO-  ENVIRONMENTAL NICHES THAT SUSTAIN THE TUMOR-  PERPETUATING POTENTIAL OF THE CELLS.  BOTH CSCS 
AND NON-CSCS CAN DISPLAY MIGRATORY BEHAVIOR AT THE INVASIVE FRONT OF PR IMARY TUMORS,  FREQUENTLY ASSOCIATED WITH 
AN EMTDISSEMINATED NON-CSCS MAY CONVERT INTO METASTATIC STEM CELLS THROUGH STILL POORLY UNDERSTOOD PROCESSES 
OF PHENOTYPIC PLASTICITY. METASTATIC STEM CELLS  MAY GENERATE PROGENY AND GIVE RISE TO OVERT METASTASIS RIGHT AFTER 
INFILTRATING THE HOS T TISSUE.  MORE FREQUENTLY,  HOWEVER,  DISSEMINATED CANCER CELLS ENTER A DORMANT STATE THAT CAN 
LAST FOR DECADES AND IS  LARGELY RESISTANT TO CURRENT THERAPIES .  UPON EXIT FROM QUIESCENCE,  METASTATIC STEM CELLS MAY 
REGENERATE THEIR LINEAGE IN THE HOST ORGAN AND RELEASE METAS TATIC PROGENY INTO THE CIRCULATION TO START SECONDARY 
LESIONS IN THE SAME OR OTHER ORGANS .  
Recent lineage tracing experiments in mouse models provide genetic evidence that primary 
tumors of the brain, colon, and skin comply with this organization 64,70,74,86. It remains to be 
determined whether metastases arising from these tumors retain a similar hierarchy. 
Nevertheless, because the long-term growth capabilities of these and other cancers relies on 
CSCs, the idea that a so-called metastatic stem cells  in these cases may be primary CSCs that 
resume their regenerative potential at metastatic sites is of interest . 
An alternative route to metastatic stem cells status is based on regaining tumor-initiating 
capacity through phenotypic plasticity. This possibility is suggested by several observations. 
In cell line xenograft models, breast cancer stem-like cells can arise from non-stem 
populations as a result of stochastic transitions between both states 87. 
EMT has been shown to result in cancer cells with stem cell-like characteristics that have a 
propensity to invade surrounding tissue and display resistance to certain therapeutic 
interventions.  
Recent studies have demonstrated that the EMT can induce non-CSCs to enter into a CSC-like 
state 72,88. As such, the EMT confers on epithelial cells precisely the set of traits that would 
empower them to disseminate from primary tumors and seed metastases 20. Hence, it is an 
attractive solution to understanding the mechanics of dissemination. Moreover, the 
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heightened resistance to apoptosis that is integral to cells generated by an EMT is surely 
critical to the ability of carcinoma cells to survive the rigors of the voyage from primary tumors 
to sites of dissemination 89. In addition, the CSC-like state approached by carcinoma cells that 
have passed through an EMT may be critical in their sites of dissemination for launching new 
colonies of cancer cells. Merely because the EMT is an attractive solution does not make it 
unique, however, and it remains possible that other still-undiscovered biological programs 
operate in carcinoma cells as drivers of malignancy.  
Recent data, for example, also implicate a role for TGFβ in regulating breast cancer stem cell 
phenotypes 72,88 and have demonstrated its essential role in maintaining the pluripotency of 
human embryonic stem cells 90; the latter may indicate a role of this pathway in inducing stem 
cell states during all phases of ontogeny. 
As mentioned, Notch signaling also has a role in the regulation of EMTs occurring during both 
embryogenesis and tumorigenesis 91 . The complexity of Notch signalling derives from the 
involvement of multiple receptors, ligands and downstream mediators. Moreover, the 
outcome of Notch activation is cell type-specific and can be either oncogenic or tumor 
suppressive 91 . Notch can also induce an EMT by activating the nuclear factor-κB (NF-κB) 
pathway 92 or by modulating the activity of TGFβ signaling. Hedgehog signaling has also been 
implicated in EMT and cancer metastasis 91. 
Thus, it appears that signaling pathways involved in the regulation of stem cell function and 
niche–stem cell interactions can play some part in triggering EMT programs, potentially 
connected with the role of these programs in establishing and maintaining stem cell-like 
characteristics. 
This is consistent with the concept of “migratory cancer stem cells”  55 and provides a link 
between the EMT program and the characteristics associated with CSCs [Figure 9]. 
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F IGURA 9 EXPRESSION OF STEM CELL- AND EMT-MARKERS IN COLORECTAL CANCER PROGRESSION 55. THE IMAGES SHOW SERIAL 
HISTOLOGICAL SECTIONS FOR EACH PROGRESSION STEP WITH SPECIFIC PROTEIN STAINING SHOWN IN BROWN. STEM-CELL-ASSOCIATED 
WNT TARGET GENES,  SUCH AS SURVIVIN,  ARE EXPRESSED ONLY IN THE BASIC REGION OF NORMAL COLONIC CRYPTS (THIN ARROW IN 
LEFT PANEL OF IMAGES),  BUT ARE DISTRIBUTED THROUGHOUT ALL AREAS OF BENIGN ADENOMAS,  CARCINOMAS AND METAS TASIS,  
INCLUDING DIFFERENTIATED (THICK ARROWS)  AND DEDIFFERENTIATED (THIN ARROWS) TUMOUR CELLS . IN CONTRAST,  EPITHELIAL TO 
MESENCHYMAL TRANSITION (EMT)-ASSOCIATED WNT TARGETS (SUCH AS L1CAM  AND LAMC2)  ARE NOT EXPRESSED IN NORMAL 
MUCOSA,  ADENOMAS AND DIFFERENTIATED TUMOUR AREAS (THICK ARROWS). EXPRESSION IS  MAINLY SEEN IN DISSEMINATED 
TUMOUR CELLS THAT HAVE HIGHEST NUCLEAR Β-CATENIN AT THE TUMOUR HOST INTERFACE (THIN ARROWS),  MOST OF WHICH RETAIN 
EXPRESSION OF STEM C ELL MARKERS . L1CAM,  L1 CELL ADHESION MOLECULE;  LAMC2,  Γ2  CHAIN OF LAMININ. 
However, the relationship between EMT and stemness is another controversial issue in 
tumorigenesis, as it was later shown that fibroblasts must undergo a MET to complete the 
initial reprogramming of fibroblasts to iPSCs 57,58. 
Several characteristics of CTCs make them likely candidates to occupy and thrive in these 
foreign sites. It is theoretically possible that only CSCs within tumors have the ability to initiate 
and sustain cancer growth. It has been known for years that just one cell can initiate a 
metastatic lesion 93.  
The inherent plasticity of stem cells makes them more adept to survive in a foreign 
environment (albeit primed by the pre-metastasis niche) where growth factors and other 
signaling molecules are different than in the primary tumor site. Increased genetic instability 
in CSCs is also likely to provide a selective advantage in adapting to foreign sites. However, it 
remains to be seen how CTCs are capable of forming metastasis at different sites.  
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Cell populations capable of generating metastasis when transplanted into mice can be isolated 
from primary tumor samples via stem cell marker genes 75,77. Circulating  tumor cells 
expressing both mesenchymal and stem cell markers have been detected in the blood of 
breast cancer patients , and when inoculated into immunodeficient mice these cells generated 
bone, liver, and lung metastases 94,95. 
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Esophageal cancer  
 
The worldwide overall incidence of esophageal carcinoma (EC) is on the rise. Esophageal 
cancer is a global problem for which no formalized screening programs currently exist. 
This cancer is the eighth most common cancer worldwide, with an estimated 456,000 new 
cases in 2012 (3.2% of the total), and the sixth most common cause of death from cancer with 
an estimated 400,000 deaths (4.9% of the total) [source http://globocan.iarc.fr/]. 
Esophageal cancer is extremely aggressive nature and poor survival rate 96,97, it exhibits 
epidemiologic pattern distinct from all other cancers 98,99.  Worldwide simple maps of Age-
standardized incidence rates per 100,000 of 2008 VS 2012 is showed in Figure 10; Worldwide 
simple maps of esophageal cancer mortality of 2008 VS 2012 is showed in Figure 11. 
 
F IGURE 10 ESOPHAGEAL CANCER- AGE-STANDARDIZED INCIDENCE RATES PER 100,000  WORLDWIDE—2008  100 VS 2012 
ESTIMATES [FROM GLOBOCAN .  AVAILABLE FROM : HTTP://GLOBOCAN. IARC.FR ACCESSED GEN. 2016] 
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F IGURE 11  ESOPHAGEAL CANCER MOR TALITY WORLDWIDE—2008  100  VS  2012  ESTIMATES  [FROM GLOBOCAN .  AVAILABLE FROM : 
HTTP://GLOBOCAN. IARC.FR ACCESSED GEN. 2016] 
The pathogenesis of esophageal cancer remains unclear. Data from studies in animals suggest 
that oxidative damage from factors such as smoking or gastro-esophageal reflux, which cause 
inflammation, esophagitis, and increased cell turnover, may initiate the carcinogenic process 
101.  
Pathology and anatomy 
 
Cancer of the esophagus typically occur in one of two forms, squamous cell carcinomas (ESCC), 
arising from the stratified squamous epithelial lining of the organ, and adenocarcinomas 
(EAC), affecting columnar glandular cells that replace the squamous epithelium 102. Despite 
the epidemiological differences, both types of esophageal cancer have a dismal prognosis. 
The natural histories of squamous cell carcinomas and adenocarcinomas of esophagus appear 
to differ substantially. For squamous cell cancers, transition models have described squamous 
epithelium undergoing inflammatory changes that progress to dysplasia and in situ malignant 
change 103.  
Most adenocarcinomas, however, tend to arise in the distal esophagus from columnar-lined 
metaplastic epithelium, commonly known as Barrett’s esophagus 104, which replaces the 
squamous epithelium during the healing reflux esophagitis and may progress to dysplasia.  
For both esophageal cancer subtypes there is a well-described pre-invasive stage illustrated 
in Figure 12. 
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F IGURE 12 | PATHOLOGICAL SEQUENCE OF OESOPHAGEAL CANCER PROGRESSION 100. PROGRESSION OF “A”   NORMAL SQUAMOUS 
EPITHELIA TO “B”  SQUAMOUS HIGH-GRADE DYSPLASIA AND “C”  SQUAMOUS-CELL CARCINOMA.  PROGRESSION OF “D”  BARRETT’S 
OESOPHAGUS TO “E”  GLANDULAR HIGH-GRADE DYSPLASIA  AND “F”ADENOCARCINOMA. THE SECTIONS WERE STAINED WITH 
HAEMATOXYLIN AND EOS IN AND ARE DISPLAYED AT ×100 MAGNIFICATION  
Cancers that start at the area where the esophagus joins the stomach (the GE junction), which 
includes the cardia, tend to behave like esophagus cancers (and are treated like them, as well), 
so they are grouped with esophagus cancers. Approximately three quarters of all 
adenocarcinomas are found in the distal esophagus, whereas squamous-cell carcinomas are 
more evenly distributed between the middle and lower third.  
Prognosis 
Esophageal cancer is the sixth most common cause of cancer deaths and its five- year survival 
is about 16% and 10% in USA and in Europe, respectively 105.  
After esophageal resection the five-year survival rates were 20.6% in a Western meta-analysis 
for unselected patients 106 and 50% for EAC patients operated with two-field 
lymphadenectomy 107. At the time of diagnosis, more than half of the patients were suffering 
from inoperable disease 108. In a large analysis of 1059 operated EC patients from a single 
German centre, Siewert et al. found better long-term prognosis for EAC than for ESCC. During 
the years 1982 to 2000, the overall resection rate was 68.2% and 75.5% for patient with EAC 
and 64% for patients with ESCC. 
More than two thirds of all patients with EC develop local recurrence or distant metastases 
and die despite complete resection of the primary tumor and multimodal treatments. 
Recurrence or metastasis results from clinically occult minimal residual disease caused by 
circulating tumor cells (CTCs) or disseminated tumor cells 109,110. 
Staging system 
Esophageal cancer staging is defined by the American Joint Committee on Cancer (AJCC) 
Staging System that establishes tumor-node-metastasis (TNM). 
Sub-classifications based on the depth of invasion of the primary tumor (T), lymph node 
involvement (N), and extent of metastatic disease (M). The most recent, 7th edition of the 
AJCC Cancer Staging Manual for esophagus and esophagogastric junction cancers was 
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developed based on a database of 4,627 esophagectomy patients who were not treated with 
induction or adjuvant therapy 111 see Figure 13. This data from 13 institutions in five countries 
and three continents was collected by the Worldwide Esophageal Cancer Collaboration 
(WECC) 112.  
 
F IGURE 13 AJCC7TH EDITION- ESOPHAGEAL  CANCER STAGING GROUPING [MODIFIED FROM 113] 
The Society of Thoracic Surgeons has published guidelines on the diagnosis and staging of 
patients with esophageal cancer 114. The work-up for esophageal cancer often starts when 
patients present with symptoms such as dysphagia and weight loss in the setting of an 
unremarkable physical exam 115. Therefore, the most common tests used to initially identify 
and diagnosis esophageal cancer are upper gastrointestinal (GI) tract contrast studies and 
upper endoscopy with biopsy. After a histologic cancer diagnosis has been obtained, 
subsequent studies are performed to determine clinical stage as accurately as possible before 
treatment is initiated. Obtaining a computed tomographic (CT) scan of the chest and abdomen 
with both oral and intravenous contrast should be the first staging study when esophageal 
cancer is diagnosed histologically. The CT scan is somewhat limited in defining the local extent 
and nodal involvement of esophageal cancer but is most useful in identifying the presence of 
distant disease such as liver or lung metastases.  
Positron-emission tomography (PET) scans improve staging by detecting previously 
unsuspected metastatic disease in up to 15-20% of patients and should be considered in place 
of CT scans or as an additional study when the CT scan does not show metastatic disease 116,117. 
Performance of the above staging modalities establishes the pre-treatment clinical stage 
which can be used to guide subsequent treatment. Distant metastases are unfortunately 
missed even with completion of the staging evaluation described above. Small liver or lung 
metastases can be missed by both PET and CT scans, and patients can also have undetected 
pleural or peritoneal disease 118. Staging via minimally invasive surgical techniques of 
thoracoscopy and laparoscopy improves the accuracy of the above non-invasive testing 118–
120. Use of these invasive techniques is relatively uncommon but should be considered in select 
patients, such as those who may be considered to have a high risk of treatment-related 
complications.  
An appropriate staging system is essential for determining treatment strategies, especially 
those involving neo-adjuvant treatments, in patients with EC. Despite the availability of 
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several preoperative diagnostic techniques, accurate pretreatment staging remains 
inconsistent. Therefore, a novel tool for early tumor detection, adequate prognostic staging, 
and accurate therapy monitoring in EC is urgently needed. 
 
CTC & esophageal cancer 
Despite the aggressiveness of esophageal cancer, a little number of research was conducted 
to understand the role of CTCs on this disease. 
Pioneering  studies from 2004 using reverse transcriptase-polymerase chain reaction provided 
a CTC detection rates ranging from 2% to 32.9% in esophageal cancer patients 121,122 
Lack of methodological uniformity, nucleic acid-extraction protocols and molecular marker 
selection as well as the inconsistent definition of CTC positivity in polymerase chain reaction-
based methods may account for this large variation. Despite methodological shortcomings, 
early study in patients before and after surgery, brought attention about CTCs presence as an 
independent predictor of disease recurrence in esophageal squamous cancer 121.  
With the introduction of CellSearch system, designed to detect CTC in peripheral blood 
samples by using immunomagnetic enrichment, there was an outbreak of studies 
enumerating circulating tumor cells in different cancers starting from those metastatic.  
It took about ten years from the establishment of CTCs (EpCAM+/CKs+/CD45-) as an 
independent predictor of progression-free survival (PFS) and overall survival (OS) in patients 
with metastatic breast cancer (MBC) 1 to investigate these cells in esophageal cancer. 
In 2013 a small pilot study in a cohort of 18 patients with advance esophagogastric cancer 
illustrated a 44% proportion of patients with more than 2 CTC/7.5ml of blood before first line 
chemotherapy 123. Only 11 patients of the 18 displayed exhibited cancers ascribable to 
esophagus: 9 esophagogastric junction, 2 esophagus. Only 4 patients had more than 2 CTCs of 
the 9 with esophagogastric cancers whereas none of the patients with esophageal cancer 
showed more than 2 CTCs. Unfortunately this study didn’t explain anything about the 
relationship between CTCs and esophageal cancer. Moreover  the established cutoff of 2 CTCs 
per 7.5ml of blood is supported only  by a large study including a wide variety of cancers at 
different stages 124 bringing the cutoff-choice perhaps too rough. 
A larger and well-defined study to assess CTCs as a staging tool for non-metastatic esophageal 
cancer into defined prognostic subgroups was  carried out by the group of Reeh 125. 
Using a strict cutoff of 1 CTC or more they found that CTC-positive patients with non-
metastatic disease had a significantly shorter overall and relapse-free survival than patients 
without CTCs (Figure 14-15).  
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F IGURE 14 OUTCOMES OF PATIENTS WITH EC WITH CTCS COMPARED WITH PATIENTS WITHOUT CTCS. CORRELATION OF OVERALL 
(A) AND RELAPSE-FREE SURVIVAL (B) WITH CTCS IN PATIENTS WITH EC  (N = 91) 
 
F IGURE 15 OUTCOMES OF PATIENTS WITH EC WITH CTCS COMPARED WITH PATIENTS WITHOUT CTCS. CORRELATION OF OVERALL 
SURVIVAL WITH CTCS IN PATIENTS WITHOUT DISTANT METASTASES (M0) (N = 86). 
In particular, 3 of the 29 patients (10.3%)  with SSC showed 1 CTCs or more, 14 of the 68 
patients  (20.6%) with adenocarcinoma showed 1 CTCs or more this could be due to different 
characteristics between esophageal cancer subtypes (SSC vs EAC) 125. 
Consistent with this hypothesis, the elegant study of Stoecklein et al reported that EpCAM 
expression in early esophageal cancer may vary 126. Analysis of EpCAM status on disseminated 
tumor cells (DTC) derived from lymph nodes and bone marrow showed that CK18 positive 
DTCs often lack of EpCAM expression [Figure 16]. 
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F IGURE 16 VARIABLE EXPRESSION OF EPCAM IN DISSEMINATED TUMOR CELLS 126.  BONE MARROW ASPIRATES  WERE STAINED WITH 
ANTIBODIES SPECIFIC FOR EPCAM AND CK18  WITH FLUORESCENCE-LABELED SECONDARY ANTIBODIES. REPRESENTATIVE 
FLUORESCENCE MICROSCOPY PICTURES OF EPCAMHIGH/CK18NEGATI VE,  EPCAMHI GH/CD18POSI TI VE AND EPCAMNEGATI VE/CK18POS ITIV E 
SAMPLES ARE DISPLAYED. 
CK18 DTCs were detected in 38.9% of esophageal cancer patients but co-expression of EpCAM 
was seen in 37.1% of cases, 62.9% revealed a DTC CK18+/EpCAMlow/negative; comparison of 
EpCAM expression on 14 antilogous pairs of primary tumors and their associated DTCs 
revealed an absence of EpCAM on DTCs in 64% of patients with EpCAM high expression primary 
tumors. 
This discrepancy was not due to an intrinsic characteristic of primary tumor but EpCAM 
knockdown and EMT induction experiments using esophageal squamous cancer cell lines 
indicate that the reduction of EpCAM expression is associated with cell migration. 
Both EpCAM positive and EpCAM negative/low cancer cells sustain metastatic progression 
during esophageal cancer in a context-dependent manner. 
Taking together these findings lead to the hypothesis that CTC studies supported by CellSearch 
may be most likely partial due to the EpCAM down-regulation observed in DTCs. EpCAM must 
not to be used as the only CTCs identification marker as it could underestimate the amount of 
circulating and/or disseminated tumor cells.  
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Focus on markers 
Epithelial CTCs (epithelial-tag) 
At single cell level, besides lack of expression of CD45 (leucocytes marker), we can define a 
CTC on at least two criteria of expression of specific proteins, e.g., epithelial cellular adhesion 
molecule EpCAM and Cytokeratin 8,18,19 127. These identification criteria provide the FDA 
approved definition of CTC 128. Such a definite statement during the last five-years 
encountered many revisions, most notably because of major advances in the field of EMT 
129,130. Indeed, in the last three years some pioneering laboratories identified non-canonical 
CTCs able to grow in vitro 94,131 bringing solid confirmations of CTC heterogeneity. 
The three most well-known families of antigen characteristics that may be present alone or in 
different combination on CTCs are the epithelial, the mesenchymal and the stemness markers. 
Six markers (plus CD45 as a negative marker) were choosen to identify circulating esophageal 
cancer cells and to comprehend a “wide” range of CTC characteristics. 
EPCAM  (EPITHELIAL TAG) 
EpCAM is a cell surface glycoprotein highly expressed in epithelial cancer cells and at lower 
level in normal epithelial cells 132. EpCAM was the starting point of detection and enumeration 
of CTCs and is particularly exploited by CellSearch system (Veridex, Warren, New Jersey, USA) 
133. Yet, expression of this protein is dependent on the stage of EMT.During EMT, it can be  
down-regulated in parallel to the increase of expression of N-cadherin and vimentin, and could 
finally disappears, as E-cadherin does. Numerous antibodies against EpCAM were used to 
target epithelial cancer cells. It is well known from the paper of Rao et al. that EpCAM 
expression is down-regulated in many CTCs 134 [Figure 17]. If patients with undetectable CTCs 
by EpCAM-based technology have a more favorable prognosis compared to those with 
detectable CTCs, there may be other CTC-negative patients with a bad prognosis. The latter 
could have undetectable CTCs due to EMT which down regulates epithelial marker expression. 
This is particularly true for EpCAM and cytokeratins (Cks).  
 
F IGURE 17 CTCS POSITIVE FOR EPCAM 135. DIFFERENT LEVELS OF EXPRESSION OF EPCAM FROM NEGATIVE A,  WEEKLY B AND 
POSITIVE C   
E-CADHERIN (EPITHELIAL TAG) 
E-cadherin is a component of adherens junctions and one of the hallmarks of epithelial cells. 
This molecule functions in close cooperation with the actin cytoskeleton and enables 
resistance to forces causing cell detachment. It is implicated to support epithelial tissue 
architecture. Expression regulation of E-cadherin has a major role in the EMT progression. 
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When a cell is going towards the mesenchymal state, expression of this protein is decreased 
136. Once cancer cells escape from primary tumor, E-cadherin can be inactivated or down-
regulated by different mechanisms. Its down-regulation can be done through promoter 
hypermethylation, histone deacetylation, and more importantly, transcriptional repression 
137. Major E-cadherin repressors are Snail and Slug. Snail appears to be the most important E-
cadherin repressor related to tumor progression. TGFβ represses both Id proteins (Inhibitor 
of DNA-binding proteins) and activates Snail family members, explain the links between TGFβ 
signaling, E-cadherin repression and EMT initiation 138. Examples of CTCs positive for E-
cadherin in Figure 19 
CYTOKERATINS (CKS)   
Cks are the largest and most diverse class of intermediate filaments which constitutes 
cytoskeleton components. At least twenty different Cks can be expressed. They are markers 
of normal epithelial differentiation, but they can be used as diagnostic tool to detect different 
circulating cells of carcinoma [Figure 18]. To this aim, antibodies must be able to recognize 
most of the more conserved epitopes. Epithelial cancer cells often express Cks 8, 18 and 19, 
and are used by Cell SearchTM   in addition to EpCAM to count  epithelial CTCs. They have also 
been used to identify disseminated tumor cells (DTCs). However, when EMT is ongoing their 
expression is often down-regulated 29. Cells leaving the primary tumor intravasate into the 
blood and often lose their Ck expression, escaping “standard” CK-based detection. Joosse et 
al. demonstrated that the use of an anti-Ck antibody cocktail is able to track cells loosing 
partial epithelial phenotype. These results suggest that CTCs showing mesenchymal state 
could have, among numerous Cks, a residual expression of some of them 139. 
 
F IGURE 18 EXAMPLES OF CTCS CYTOKERATINS POSITIVE. A CTC COUNTERSTAINED WITH DAPI (BLUE)  PANCK  (GREEN) BY ICHIP 
TECHNOLOGY 140;  B  EXAMPLES OF CTCS IDENTIFIED WITH CELLSEARCH DAPI  (PURPLE)  PANCK (GREEN)141 
Mesenchymal/Stem CTCs (mesenchymal/stem-tag) 
Differentiated epithelial carcinoma cells can be transformed into a mesenchymal state and 
during this process, different degrees of EMT occur. Then it can be difficult to define a pure 
mesenchymal CTC subpopulation. However the mesenchymal character of CTCs can be 
assessed by the expression of protein/s reflecting EMT process.  
In addition, during EMT, cancer cells are endowed with stemness characteristics acquiring 
migratory properties. This is one of the hypothetical origin of circulating-cancer stem cells 
(CSC) 130. 
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Thus the diversity of CTCs having EMT features, which can be relevant in either CSCs or 
differentiated cancer cells, underlines the difficulty to choose significant identification 
markers.  
N-CADHERIN  
Adherens junctions have a major role in the shape organization of epithelial tissue. Phenotypic 
changes leading to epithelial sheet movements are based on their modifications. Among 
proteins of adherens junctions, classic cadherins are  the E-cadherin and N-cadherin 
subfamilies. N-cadherin is expressed in many cells and particularly in mesenchymal cells. 
Therefore it is normally used as a marker of EMT. During this process E-cadherin is switched 
off while N-cadherin is switched on. Abnormal expression of N-cadherin associated to a 
dramatic decrease of E-cadherin is a hallmark of mesenchymal character of CTCs resulting 
from E- to N-cadherin switch 142 [Figure 19]. Loss of E-cadherin in tumor cells is due to 
methylation of its promoter or to overexpression of transcriptional repressors which target its 
promoter 143,144. 
 
F IGURE 19 EXAMPLES OF CTCS DIFFERENTLY POSITIVE FOR N-CADHERIN,  E-CADHERIN OR CKS.145 
CD44V6 
CD44 is a widely expressed polymorphic integral membrane adhesion molecule that binds 
hyaluronic acid and contributes to cell-cell and cell-matrix adhesion, cell growth and 
trafficking, EMT, and tumor progression 146. CD44 transcripts undergo complex alternative 
splicing, resulting in functionally different isoforms expressed primarily on epithelial cells 147. 
Among CD44 isoforms (CD44vn), CD44v6 seems to play a major role in cancer progression for 
its ability to bind hepatocyte growth factor (HGF), osteopontin (OPN), and other major 
cytokines produced by tumor micro- environment 146. The major role of CD44v6 involves cell 
migration and invasion. CD44v6 interacts with hepatocyte growth factor receptor (MET) in the 
presence of HGF and potentiates its signaling 148. Studies indicated that increased CD44v6 
expression would induce a high metastatic potential in some tumors, such as non-small cell 
lung cancer149, gastric cancer 150, and pharyngolaryngeal cancer 151. In a recent meta-analysis 
where single studies concerning esophageal cancer and presence of CD44v6 were pooled 
together, the results suggested that the expression of CD44v6 was higher in esophageal cancer 
tissue than in normal tissue 152. Results also found that the high expression of CD44v6 was 
associated with poor survival in esophageal cancer patients with lymphoid nodal metastasis, 
which suggests that the abnormal expression of CD44v6 in tumor cells may enhance their 
potential form metastasis in the regional lymph nodes [Figure 20]. However, no association 
was observed between the expression of CD44v6 and the tumor stage and histological types, 
indicating that CD44v6 may not be involved in the biological function of tumor cells but may 
promote the metastasis of tumor cells.  
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F IGURA 20  CD44V6  EXPRESSION DURING TUMOR PROGRESSION 94.  IMMUNIHISTOCHEMISTRY OF TWO SECTIONS OF PRIMARY TUMOR 
IN PATIENTS M0 AND AFTER PROGRESSIO N TO BONE METASTASES,  BOTH EXPRESSED CD44V6 BUT AT DIFFERENT LEVELS 
ABCG2 
ATP binding cassette (ABC) transporters form one of the largest trans-membrane protein 
families. These proteins use cellular ATP to drive the transport of various substrates across cell 
membranes including drugs, metabolites and other compounds. Human ABCG2 is the second 
member of the G-subfamily of ABC transporters. ABCG2 was first cloned from doxorubicin-
resistant human MCF-7 breast cancer cells and named as breast cancer resistance protein 
(BCRP) 153 ABCG2 is widely distributed in normal tissues and is highly expressed in a 
subpopulation of stem cells. Its conserved expression in stem cell populations suggests an 
important role in stem cell biology. In addition, ABCG2 is one of the most important multidrug-
resistance transporters and its substrates include many commonly used drugs in cancer 
chemotherapy 154. There is increasing evidence that ABCG2 correlates with unfavorable 
prognosis in a variety of tumors 155. In a study conducted in a large cohort of esophageal cancer 
patients (100), ABCG2 expression was found in 61% of tumor tissues [Figure 21]. The 
expression of ABCG2 was correlated with poor survival being an independent prognostic 
factor 156.  
 
F IGURE 21 IMMUNOHISTOCHEMICAL OF ABCG2  IN TUMOR TISSUES OF ESCC. A SLIDE REPRESENTATIVE OF POSITIVE ABCG2 
EXPRESSION,  IN POORLY DIFFERENTIATED ESCC.  B  SLIDE REPRESENTATIVE OF NEGATIVE ABCG2  EXPRESSION,  SHOWN IN 
MODERATELY DIFFERENTIATED ESCC.  
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Aims and Study design 
Primary aims  
 To assess the feasibility of circulating esophageal cancer cells enrichment and their 
characterization  
 To evaluate the prognostic value of Circulating Esophageal Cancer Cells in esophageal 
cancer  
Secondary aim 
 to characterize  the identified cells,  by molecular assays through cancer-related genetic 
alterations that will be identified by next generation sequencing (NGS) approaches. 
Design 
Blood samples (15-20 ml) from untreated/naive patients affected by metastatic and non-
metastatic esophageal cancer will be assessed, including cervical esophagus, upper-middle-
lower esophagus, esophagogastric junction. 
Samples will be collected before primary therapy of choice (radio-therapy, radio-
chemiotherapy, radio-chemiotherapy), one month after therapy  and, when possible, after 
surgery. For experimental Workflow see Figure 1. 
Expected Outcomes 
 To confirm the feasibility of the detection of CTCs in a pathology where they are still poorly 
studied 
 To characterize CTCs in this disease  
 To investigate the correlation of CTCs  and survival, progression-free survival and 
anatomical district 
 To investigate a potential biological  explanation for esophageal cancer aggressiveness
 
F IGURE 1 EXPERIMENTAL WORKFLOW  




Materials and Methods 
Cell culture 
Breast cancer cell lines MDA-MB 436, MDA-MB 231, MCF7  were originally purchased from 
American Type Tissue Culture. The non-tumorigenic breast epithelial cell line MCF10A, 
immortalized human mammary epithelial cells  hTERT-HMECs (named HME), and the modified 
HME-TWIST1, HME-ZEB1, HME-ZEB2 over-expressing  the EMT master transcription factors 
TWIST,  ZEB1, ZEB2 respectively, were gifted by  Professor Alain Puisieux laboratory. 
MDA-MB 436, MDA-MB 231 cell lines were cultured in  Leibovitz's L-15 medium (GIBCO) with 
10 mcg/ml insulin(Sigma Aldrich), 100U/ml penicillin-streptomycin (GIBO), 2mM glutamine 
(GIBCO) complemented with 10% FBS (GIBCO), in a non free-gas exchange condition.  
MCF7 cell line were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) medium 
(GIBCO) 100U/ml penicillin-streptomycin (GIBCO), 2nM glutamine (GIBCO) complemented 
with 10% FBS (GIBCO).  HMEC-derivatives were cultured in 1:1 DMEM/HAMF12 medium 
(GIBCO) complemented with 10% FBS (GIBCO), 100 U/ml penicillin-streptomycin (GIBCO), 2 
mM L glutamine (GIBCO), 10 ng/ml human epidermal growth factor (EGF) (Millipore), 0.5 
mg/ml hydrocortisone (Sigma Aldrich) and 10 mg/ml insulin (Sigma Aldrich) as previously 
reported 88  
MCF10A cell line were cultured in DMEM/F-12, GlutaMAX™ medium (GIBCO) complemented 
with 5% Horse Serum (New Zealand origin) (GIBCO), 100 U/ml penicillin-streptomycin (GIBCO), 
2 mM L glutamine (Invitrogen), 100 mg/ml human epidermal growth factor (EGF) (Millipore), 
1 mg/ml hydrocortisone (Sigma), 1mg/ml cholera toxin (Sigma Aldrich) and 10 mg/ml insulin 
(Sigma Aldrich), 100U/ml penicillin-streptomycin (GIBCO) as mentioned  157 . 
All cell lines were maintained as a monolayer in a 37°C incubator with 5% CO2 and sub-
cultured  at 70-80%  confluence (approximately twice weekly). 
EMT induction 
MCF10 cell line were cultured on 19,5cm2 petri dish (BD Falcon), using previously described 
culture medium. Epithelial to mesenchymal transition were induced by treating cells with 
10ng/ml TGF beta1 (Peprotech) every 48 hours or during sub-culturing.  
Peripheral Blood Monuclear cells (PBMC) isolation 
PBMC were isolated from healthy donor peripheral blood (PB). About 3ml of PB were drawn 
in EDTA tubes (BD Vacutainer, Becton Dickinson).A density gradient separation by Lymphocyte 
Separation Media (BioWest) was subsequently performed (400g centrifugation for 30 
minutes). From the resulting blood stratification, the mononuclear cells (PBMC) interphase 
was carefully collected, washed and re-suspended in PBS1X. If samples had an erythrocyte 
contamination, a red blood lysis was performed by ACK lysis buffer (Lonza). 
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Immunofluorescence  
Since original HME and their modified descendant cells are putative models of different levels 
of EMT, they were tested with a immunofluorescence assay based on a two antibodies 
combination to verify their levels of Epithelial-to-mesenchymal transition. 
All the four types of HME cells were cultured on cover-glass and stained with anti-Vimentin 
FITC (BD Biosciences) and anti-E-cadherin (Miltenyi) both with a diluition of 1:100. Differences 
between the positivity of these two markers reflect different levels of EMT: E-cadherin + / 
Vimentin – identifies epithelial cells, E-cadherin – / Vimentin + identifies mesenchymal cells, 
whereas  E-cad+/Vim+ reveals intermediate levels of EMT. 
DEPArray calibration settings  
Since DEPArray system is a fluorescence microscope-based lab-on-a-chip (see Appendix 2 for 
details), a preliminary setup was needed in order to detect only specific signals.  
The brightest fluorochromes respectively PE and APC were selected for Epithelial and 
Stem/Mesenchymal tags, respectively. FITC channel was designed to identify lymphocytes 
marker CD45. DAPI was used to counterstain cell nuclei. 
A three steps setup was carried out with MDA MB436 cell line and PBMC stained with different 
clusters of antibodies (one tag per step). The first the two cell types mix was stained for the 
Epithelial tag and CD45, the second for the Stem/Mesenchymal tag and CD45 and the third 
with all tags and CD45. 
Briefly,  cells were firstly stained with primary antibodies for membrane targets. After 
membrane labeling, samples were rinsed and fixed by Inside Fix Buffer (Miltenyi), 
permeabilized using Inside Perm buffer (Miltenyi) and labeled for intracytoplasmic targets.  All 
the antibodies used were monoclonal and conjugated with a specific fluorochrome.   
For a detailed specification of antibodies refers to Table1 
Antibody Fluorochrome Clone Manufacturing Dilution   
EpCAM PE HEA-125 Miltenyi 1:10 
Pan CK PE C11 Aczon 1:10 
E-cadherin PE 67A4 Miltenyi 1:10 
N-cadherin AlexaFluor 647 8C11 BD Pharmingen™ 1:20 
CD44v6 APC 2F10 R&D Systems 1:20 
ABCG2 APC 5D3 R&D Systems 1:10 
CD45 AlexaFluor 488  GA90 Aczon 1:14 
TABLE1 ANTIBODIES SPECIFICATIONS 
 
For a detailed scheme of samples and antibodies, see Tables 2-4. 
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Cell types Experiment 3 Antibody Fluorochrome 
Lymphocytes 
EPITHELIAL TAG 
STEM/MESENCYMAL  TAG 
LYMPHOCYTE 
EpCAM PE 
Pan CK PE 
E-cadherin PE 
N-cadherin AlexaFluor 647 
CD44v6 APC 
ABCG2 APC 
CD45 AlexaFluor 488  
TABLE 2  EXPERIMENT 1  SPECIFICATIONS 






Pan CK PE 
E-cadherin PE 
CD45 AlexaFluor 488  
TABLE 3  EXPERIMENTS 2  SPECIFICATIONS 






N-cadherin AlexaFluor 647 
CD44v6 APC 
ABCG2 APC 
CD45 AlexaFluor 488  
TABLE 4  EXPERIMENT 3  SPECIFICATIONS 
During  DEPArray “Scan” step every channel exposure times was adjusted to minimize 
unspecific signals (e.g. autofluorescence traceable by FITC channel) and to display only distinct 
signals. 
Grab all assay on EMT inducted cell lines 
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The muti-phenotypic tag Grab all-assay was tested on the two different EMT models: MCF10A 
treated with TGF beta and HME transfected with EMT master regulators TFs.  
In order to arrange a wide EMT spectrum modification, samples of MCF10A treated cells were 
collected at specific time points reflecting morphological modifications. Four different stages 
of EMT on MCF10A cells were selected: at baseline, after four days, after six days and after 
ten days of treatment. 
HME, HME-TWIST1, HME-ZEB1, HME-ZEB2 cell lines were cultured at selective conditions i.e. 
for transfected cells, culture media were addicted with selective antibiotics. 
All collected samples were stained as previously described for DEAParray calibration 
experiments. 
All the analysis were performed by DEPArray system using settings previously determined. 
Grab all-assay on esophageal cancer patients and 
healthy donors  
Patients aged  ≥18 years  with a diagnosis of M0 and M1 esophageal cancer were enrolled. M1 
patients were selected as potential CTC-positive controls. Patients were treated at Irccs 
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) (Italy) between 
January 2013 and December 2015. All M0 patients received adjuvant therapy, referred as 
primary therapy (chemotherapy and radiotherapy), before surgery (referred as secondary 
therapy according to the local institutional practice).  
The blood draw from M0 patients was performed before primary treatment (1° CTC analysis), 
after primary treatment/before-secondary treatment (2°CTC analysis) and after secondary 
treatment/follow-up (3°CTC analysis). Blood draw from M1 patients was performed at 
baseline before I line chemotherapy (1° CTC analysis) after I line chemotherapy (2°CTC 
analysis) and eventually after II line chemotherapy (3° CTC analysis). 
Patients and healthy donors signed a written informed consent. This study was approved by 
the Ethics Committee of the IRST IRCCS AVR (CEIIAV) (reference L3P957) and an amendment 
dated March 2015 was approved by the CEIIAV.   
Blood sampling was carried out in EDTA Vacutainer tubes (BD).  
Three tubes were collected:  a first 3ml, which was discarded due to possible skin epithelial 
cell contamination, and two 9 ml tubes, that were utilized for the CTC test. 
 For CTCs enrichment, Oncoquick™ system was used according to manufacturer’s protocol and 
previous studies 158.Enriched samples was stained with Grab all-assay as DEPArray calibration 
protocols; the complete experiment workflow is listed in Figure 1 
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F IGURE 1 CTC  ENRICHMENT-GRAB ALL ASSAY WORKFLOW 
  Analyses were conducted using DEPArray system adopting the setting previously 
determined. After identification, CTCs were sorted as a single cell for subsequent molecular 
analyses by the “recovery manager” software of DEPArray system. For a complete scheme of 
the DEPArray system referred to Figure 2 
 
F IGURE 22 DEPARRAY ANALYSIS WORKFL OW 
Whole Genome Amplification 
Identified CTCs were recovered singly (with a 100% of purity guaranteed by DEPArray 
technology). Internal controls were 1 leucocyte, 5 leucocytes and buffer (SB115), collected at 
every DEPArray analysis.  
On single CTCs, and their respective controls we performed whole genome amplification 
(WGA) using the Ampli1TM WGA kit according to manufacturer's instructions. Ampli1 kit 
globally amplifies the genome after generation of defined DNA fragments and adaptor ligation 
using a single primer to the adaptor sequence 159. To assess the quality of single cell WGA 
samples isolated, we performed Quality Control Kit (QC) according to manufacturer's 
instruction. QC is based on multiplex PCR providing a genome integrity index (GII), defined by 
the detected PCR bands as a measure for quality of each WGA sample generated from an 
isolated single cell. 
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Results 
DEPArray calibration setup 
Preliminary setup of the microscopy equipment of the DEPArray system was carried out to 
identify the more efficient antibodies using different set of cells. 
A three steps setup was carried out with MDA MB436 cells mixed with PBMC. Cell mixes were 
stained with 3 different clusters of antibodies. Each cluster was called “tag”. The first two-cell 
type mix was stained with the Epithelial-related tag and CD45, the second with the 
Stem/Mesenchymal tag and CD45 and the third with the two previous tags and CD45. 
The first DEPArray-microscope calibration was performed using only Lymphocytes stained 
with Grab all-assay. During the Scan step (see Appendix-2), fluorescence channel exposure 
times were adjusted  to reach the best PE and APC channel intensity  and obtain images 
without aspecific signal,  and at the same time getting the maximum signal for the FITC 
channel Figure 1 
 
F IGURE 1 DEPARRAY IMAGES OF LYMPHOCYTES . EXAMPLES OF LYMPHOCYTES STAINED W ITH GRAB ALL-ASSAY,  DAPI CHANNEL 
IDENTIFY NUCLEUS,  FITC CHANNEL IDENTIFY CD45; NO UNSPECIFIC FLUORESCENCE SIGNAL FOR PE (E-TAG) AND APC (MS-TAG) 
CHANNELS . 
A second DEPArray-microscope calibration was performed with mixed MDA MB436 cell line 
and PBMC stained with only the Epithelial tag of the Grab all assay. 
The purpose of this step was to calibrate fluorescence channel settings to maximize signals of 
the PE channel (E-tag), decrease unspecific signal in the APC channel (MS-tag) and verify the 
specificity of  signals of the FITC channel (CD45) depending from PBMCs [Figure 2]. 
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F IGURE 2 DEPARRAY IMAGES OF PBMC  MIXED WITH MDA  MB 436. STAINED WAS PERFOMED WITH ONLY E-TAG ANTIBODIES AND 
CD45,  MDA MB 436 WERE POSITIVE ONLY FOR E-TAG (PE) NO ASPECIFIC SIGNAL FOR APC CHANNEL (WITHOUT SPECIFIC 
ANTIBODIES).  AQUA ARROWS INDICATE LYMPHOCYTE VISIBLE O N THE FITC CHANNEL. DAPI IDENTIFIES NUCLEUS .  
DEPArray-microscope calibration was then performed with MDA MB 436 cells mixed with 
PBMCs stained with Mesenchymal/Stem tag and CD45 only. 
The purpose of this step was to calibrate fluorescence channel settings to maximize signals of 
the APC channel (MS-tag), decrease unspecific signal of the PE channel (E-tag) and verify the 
lymphocytes specific signals of the FITC channel (CD45) [Figure 3]. 
 
F IGURE 3  DEPARRAY IMAGES OF MDA  MB 436  STAINED WITH MS  TAG AND CD45. SIGNALS WERE PRESENT ONLY FOR APC  
CHANNEL (MS-TAG) NO ASPECIFIC SIGNALS FOR BOTH FITC CHANNEL (CD45) ANA PE CHANNEL (E-TAG).  DAPI  IDENTIFY NUCLEUS  
Differently stained cell populations were visible by DEPArray, see dot plots Figure 4. MDA MB 
436 cell line was positive for E-tag or MS-tag whereas PBMC population was positive for CD45 
only.  
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F IGURE 4 DEPARRAY DOTPLOTS . ON THE LEFT,  DOTPLOT WITH E-TAG ON THE Y-AXIS AND CD45  ON THE X-AXIS-  YELLOW RECTANGLE 
ENCLOSES MDA  MB 436  E-TAG+/CD45-,  GREEN RECTANGLE ENCL OSES PBMC  E-TAG-/CD45+.  ON THE RIGHT,  DOTPLOT WITH 
MS-TAG ON THE Y-AXIS AND CD45  ON THE X-AXIS-  RED RECTANGLE ENCLOSES MDA  MB  436 MS+/CD45-,  GREEN RECTANGLE 
ENCLOSES PBMC MS-TAG-/CD45+. 
The GRAB all-assay  
 
The Grab-all assay sensitivity was tested on cell lines induced in EMT. MCF10A cell line was 
treated with TGF beta. HME cell line and the stable HME-TWIST1, HME-ZEB1, HME-ZEB2 lines, 
over-expressing  the EMT master transcription factors TWIST,  ZEB1, ZEB2 respectively 160. All 
the different cell lines were tested for EMT levels and after Grab all assay was performed. 
EMT  ON MCF10A 
Morphological EMT-related changes have been observed in treated MCF10A. Four different 
stages of induction were selected to investigate morphological changes of EMT transformed 
MCF10A: before the first treatment, after four days, after six day and after ten days Figure 5. 
Untreated cells (or before treatment) showed tightly packed clusters with a typical epithelial 
phenotype, e.g. tight cell-to-cell adhesion. These cells maintained a standard doubling time of 
48h. After 4 days of EMT induction, the peculiar epithelial tissue-like structure disappeared 
and the distinctive cobblestone-like organization was lost and  spindle-like phenotype and 
characteristic fibroblast-like morphology appeared.  
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F IGURE 5  MORPHOLOGICAL CHANGES IN MCF10A  EMT  INDUCED. AFTER 4  DAYS (4D)  OF TFG BETA TREATMENT THE COBBLESTONE-
LIKE CELLS ORGANIZATION CHANGES,  CELL MEMBRANE CRESTS  APPEARED AS A FIRST EMT INDICATOR .  DURING TGF  BETA TREATMENT 
CELL ORGANIZATION REACHED A SPINDLE-LIKE PHENOTYPE. 
GRAB ALL ASSAY ON EMT-INDUCED MCF10A 
Assay sensivity evaluation was performed on the four selected times of EMT induction of 
MCF10A. DEPArray single cell images are shown in Figure 6, DEPArray dot plots representing 
cells populations in Figure 7.  
TGF beta untreated MCF10A cells resulted have any SM-tag positivity.  
When  morphological changes started to appear (4d)  there is a reduction of the mean 
intensity of cells positive for epithelial tag but only after six days (6d) there is a an appearance 
of cells weakly positive for SM-tag . 
Ten days after the beginning TGFβ-1 treatment (1d0) cells positive for SM-tag are increasing. 
Hybrid phenotypes (E-tag and MS-tag) and cells displaying no positivity to the E-tag or MS-tag 
were present at late stages of EMT. 
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F IGURE 6 DEPARRAY IMAGES OF EMT-MCF10A STAINED WITH GRAB ALL ASSAY. REPRESENTATIVE IMAGES OF MCF10A CELLS 
AFTER DIFFERENT EXPOSURE TIMES TO TGF  BETA (RANGE 0  TO 10  DAYS).  IT IS  POSSIBLE RECOGNIZE CELLS EXPRESSING ONLY 
EPITHELIAL MARKERS (E-TAG YELLOW) OR MESENCHYMAL ANTIGENS (MS-TAG,  RED) OR HYBRID CELLS (E-TAG/MS-TAG).  EPITHELIAL 
TAGGED CELLS WERE DETECTABLE AFTER SHORT EXPOSURE TIMES,  WHEREAS MESENCHYMAL OR HYBRID CELLS WERE OBSERVED ONLY 
AT EMT LATE STAGES .  
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F IGURE 7  DEPARRAY DOTPLOT OF THE FOUR S TEPS OF EMT  INDUCTION OF MCF  10A.   EPITHELIAL TAG ON Y AXIS (PE  CHANNEL) 
STEM/MESENCHYMAL TAG ON X AXIS (APC  CHANNEL). UNTREATED MCF10A CELLS ARE REMARKABLY POSITIVE TO THE EPITHELIAL 
TAG AND NEGATIVE TO THE STEM/MESENCHYMAL TAG [BLACK DOTS],  4D MCF10A  CELLS LOOK LIKE LESS  POSITIVE TO EPITHELIAL 
TAG [RED DOTS],  6D [BLUE DOOTS]   AND 10D [PURPLE DOTS]  LOOK LIKE EVEN LESS POSITIVE/NEGATIVE TO THE EPITHELIAL TAG AND 
SOME OF THESE CELLS ARE WEAKLY POSITIVE TO THE STEM/MESENCHYMAL TAG 
EMT  ON HME  CELL LINE AND MODIFI ED HME-TWIST1,  HME-
ZEB1,  HME-ZEB2 
The  Grab all assay was performed on models of HME cell line forced in EMT: HME-TWIST1, 
HME-ZEB1, HME-ZEB2.  
Immunofluorescence experiments were conducted on all HME cell lines in order to verify their 
EMT features using E-cadherin as an epithelial cell adhesion marker and Vimentin as a 
mesenchymal marker. 
Different positivity for the two markers reflected different stages of EMT Figure 8. HME cells 
were positive only for E-cadherin. The majority of HME-TWIST1 cells had a lower positivity for 
E-cadherin and while some cells were weakly positive for Vimentin. A more defined EMT-
related profile was observed in HME-ZEB2 cells, quite negative for E-cadherin and fairly 
positive for Vimentin. HME-ZEB1 cells were positive for Vimentin only, showing the most 
prominent EMT feature.  
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F IGURE 8  EMT  FEATURES OF DIFFERENT HME  CELLS BY IMMUNOFLUORESCENCE .  EPITHELIAL HMEL  CELLS WERE E-CAD+/V IM-. 
HME-TWIST1  CELLS EXHIBIT AN INTERMEDIATE PHENOTYPE E-CAD+-/V IM+- RETAINING A COBBLESTONE MORPHOLOGY. EVEN 
HME-ZEB2  CELLS DISPLAY AN INTERMEDIATE PHENOTYPE BUT LACKED EPITHELAIL MORPHOLOGY IN FAVOR OF A MORE SPINDLE-
SHAPED MORPHOLOGY.  ZEB1  EXPRESSION ON HME-ZEB1  WAS SUFFICIENT TO PROMOTE A COMPLETE TRANSDIFFERENTIATION 
PROCESS,  GIVING RISE TO TYPICAL SPINDLE-LIKE CELL MORPHOLOGY,  AND A TOTAL LOSS OF E-CADHERIN EXPRESSION AND A TOTAL 
GAIN OF VIMENTIN EXPRESSION . DAPI (BLUE)  IDENTIFY NUCLEUS,  V IMENTIN IN GREEN COLOR,  E-CADHERIN IN RED COLOR.   
EMT features of different HME cells were observed by Grab all assays also, as expected [Figure 
9]. HMEL cells were positive only for the E-tag, HME-TWIST1 were E-tag positive but with some 
cells were weakly positive for the MS-tag. 
HME-ZEB2 cells displayed some positivity for the E-tag, combined with a fibroblast-like 
morphology. Some cells were positive for MS-tag. HME-ZEB1 cells displayed a total negativity 
for E-tag and some cells were positive for MS-tag. 
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F IGURE 9 DEPARRAY IMAGES REPR ESENTING DIFFERENT HME  CELLS REFLECTING EMT FEATURES . 
Grab all assay specificity on blood of healthy donors.  
In order to test the Grab all assay specificity, blood from healthy donors was used. No False 
positive CTCs was detected.  
Grab all assay on blood of esophageal cancer 
patients. 
METASTATIC ESOPHAGEAL CANCER PATIENTS ST RATIFICATION 
BASED ON CTCS ANALYSIS  
The number and features of CTCs detected in metastatic esophageal cancer patients are listed 
in table 1 
 
TABLE 1  CTCS NUMBER AND FEATURE ON METASTATIC ESOPHAGEAL CANCER PATIENTS . (NE:  NOT EVALUATED) 
Three  out of four patients metastatic at diagnosis (M1, M2, M4) were found to be CTC positive 
before primary treatment and died before the end of therapy.  Patient M3 was not evaluable 
     41 
 
before I line chemotherapy, but was tested for CTC evaluation and found to be positive: one 
MS-tag positive CTC was found; both epithelial CTCs and mesenchymal/stem CTCs were found 
before II line chemotherapy. 
Patients stratification is listed in Figure 10.  
 
F IGURA 10  METASTATIC PATIENTS S TRATIFICATION BASED ON CTCS. 
NON-METASTATIC ESOPHAGEAL CANCER PATIENTS ST RATIFICATION 
BASED ON CTCS ANALYSIS  
The number and features of CTCs analyzed in non-metastatic esophageal cancer patients are 
listed in table 2.  
 
TABLE 2  CTCS NUMBER AND FEATURE ON NON-METASTATIC ESOPHAGEAL CANCER PATIENTS . (NE:  NOT EVALUATED) 
Reported results showed that 4 out of 7 patients without clear evidence of metastases at 
diagnosis (NM1, NM2, NM4, NM6) did not have detectable CTCs before the beginning of 
primary treatment.  
At the second CTCs analysis, NM1 patient was positive for E-tag CTCs. At that time, a PET 
analysis showed a lymph-nodes progression disease and patient died during chemotherapy. 
NM4 patient resulted positive for second CTCs analysis (E-tag and MS-tag) also.  CT scan 
resulted in the detection of a stable disease. Surgery was then carried out, but patient died 
about six months later. 
At the second CTCs analysis, NM6 was positive for E-tag CTCs. CT analysis showed a partial 
response to therapy, whereas PET analysis exhibit a metabolic progression disease. At present, 
NM6 patient is under surgical evaluation. 
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NM2 patient resulted negative for all the three CTCs analysis. Esophagectomy surgery was 
carried out and he is currently is on follow-up.  
The other 3 non-metastatic patients (NM3, NM5, NM7) were CTCs positive at the first CTC 
analysis. In NM3 patient were found both E-tag and MS-tag CTCs and patients died before the 
end of the primary treatment. 
NM5 had only E-tag CTCs and resulted negative for subsequent CTCs analysis.  
NM7 had E-tag CTCs at first CTCs analysis, no CTCs were found on second CTCs analysis, but 
was CTCs positive for E-tag CTCs at third CTC analysis. No surgery for patients NM7 was carried 
out because of a liver tumor relapse.  
Patients stratification is listed in Figure 12. Detailed clinical histories of every patients with 
relatives CTCs status are listed in Appendix-3. 
Representative CTCs analyzed by DEPArray platform are shown in Figure 13.   
 
F IGURE 12 NON-METASTATIC ESOPHAGEAL CANCER PATIENTS STRATIFICATION BASED O N CTCS. 
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PATIENTS  CLINICAL  CHARACTERISTICS 
Patients clinical characteristics as pathogenic Siewert classification, Histology and 
differentiation grade are listed in table 3. 
 
PATIENT STAGING Histology GRADE 
M1 SIEWERT 3 Squamous carcinoma G3 
M2 SIEWERT 3 Adenocarcinoma  G3 
M3 SIEWERT 1 Adenocarcinoma G3 
M4 SIEWERT 3 Intestinal adenocarcinoma  G3 
NM1 SIEWERT 3 Adenocarcinoma  G2 
F IGURE 13 DEPARRAY IMAGES OF CTCS ISOLATED FROM ESOPHAGEAL CANCER PATIENTS. SOME CTCS WERE AS A SINGLET,  OTHER CELLS WERE 
CLUSTERED WITH LYMPHOCYTES,  INDIVIDUALIZED BY CD45  ANTIBODY. DAPI CHANNEL [PSEUDOCOLOR BLUE]  IDENTIFY NUCLEUS,  FITC  CHANNEL: 
CD45,  PE CHANNEL [PSEUDOCOLOR YELLOW]: E-TAG (EPCAM,  E-CADHERIN,PANCK),APC  CHENNEL [PSEUDOCOLOR RED]: MS-TAG (N-
CADHERIN,  CD44V6,  ABCG2). 
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NM2 SIEWERT 2 Adenocarcinoma NE 
NM3 SIEWERT 2 Signet ring cell adenocarcinoma G3 
NM4 SIEWERT 2 Signet ring cell adenocarcinoma G3 
NM5 SIEWERT 3 Adenocarcinoma G2 
NM6 NE Carcinoma NE 
NM7 SIEWERT 1 squamous carcinoma G2 
TABLE 3  PATIENTS MAIN CLINICAL CHARACTERISTICS.  NE  AS NOT EVALUATED. 
FEATURES OF PATIENTS THAT UNDERWENT SURGERY AND CLINICAL  
F.UP  
Characteristics of the 3 patients that underwent surgery are listed in table 4.  
After neo-adjuvant chemotherapy NM2 and NM5 patients exhibited a complete tumor 
regression (T0)  Instead, NM4 patient exhibited a T3 staging, underling a moderate effect of 





Figure 14 shows clinical features of surgery-patients with CTCs status. 
Reflecting CTC status, from E-tag CTC-positive to negative, NM5 experienced  a complete 
tumor regression ()(T0) . On the contrary, NM4 experienced only moderate tumor regression 
(T3) with a subsequent progression disease in parallel with a CTCs status that became positive 
(E-tag and MS-tag CTCs) after being negative before first treatment. . 
NM2 patients was always found to be CTC-negative and experience a complete tumor 
regression. 
 
F IGURE 14 PATIENTS SURGERY STATUS VS CTCS STATUS 
PATIENT yTNM Regression Degree (MANDARD) 
NM2 T0N0(0/33)M0 LV0 R0 1 
NM4 T3N0(0/8)M0 LV0  R0 3 
NM5 T0N0(0/43)M0 LV0 R0 1 
TABLE 4  FEATURES OF PATIENTS UNDERWENT SURGERY 
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Whole Genome Amplification on single CTCs 
Starting from indications of CTCs status in surgery patients, we performed WGA amplifications 
of these cells at first. All WGA products of single CTCs (including DEPArray controls) were 
quality checked by QC kit.  
WGAs from single CTCs of NM5 patient showed a low DNA quality as indicated by QC bands, 
not all samples exhibited any expected bands. Only on 7/13 (53,8%) of CTCs of NM5 patient 
could be performed a molecular analysis. 
Comparable results was obtained on single CTCs of NM4 patient, 7/10 CTCs presented a DNA 
quality suitable for molecular analysis. 
Listed below are QC results of processed samples of NM5 patients CTCs  [Figure 15] and NM4 
patients CTCs [Figure 16] . 
 
F IGURA 15 QC  RESULTS ON WGAS FROM CTCS OF NM5  PATIENTS .  1-12 S INGLE CTCS;  13  CTC  WITH LEUCOCYTE,  14 S INGLE 




F IGURA 16  QC RESULTS ON WGAS FROM CTCS OF NM4  PATIENT CTCS. 1-11  S INGLE CTCS,  12 (5) LECUCYTES,  QC CTR+/-  
(BLUE),  WGA  CTR+/-  (RED),  M MARKER  
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Discussion 
Esophageal cancer is one of the most aggressive tumors, with a long-term survival rates below 
15% due to both high frequency of local recurrence and distant metastases. One of the 
cardinal features of cancer cells is their abnormal mobility 161 that is the key feature of 
circulating tumor cells. A central tenet of cancer biology has been that cancer cells that leave 
the primary tumor (CTCs) can then seed metastases in distant organs in a unidirectional 
process.  
In the course of last ten years, few studies investigated the role of CTCs in esophageal cancer. 
Starting from pioneering studies of mRNA ascribable to CTCs121,122, through first CTCs count 
by CellSearch system without any explanation of the association of these cells with cancer 123. 
Only recently, the group of Reeh laid the cornerstone of CTCs in esophageal cancer. They 
showed that CTC positive non-metastatic patients had a significantly shorter overall and 
relapse-free survival than patients without CTCs 125. 
Even though these findings revealed a tight connection between finding CTCs and clinical 
outcome in esophageal cancer, other works 133,162 have shown that CellSearch is not the 
perfect assay, hence its FDA clearance does enable completely its use in the clinic and as a 
stratification marker in clinical trials. 
Aberrant activation of epithelial-mesenchymal transition (EMT) has been implicated in 
carcinogenesis 23,163. Consistent with this hypothesis, Stoecklein et al reporting that EpCAM 
expression in early esophageal cancer may vary 126. They hypothesized that both EpCAM 
positive and EpCAM negative/low cancer cells sustain metastatic progression during 
esophageal cancer in a context-dependent manner.  
In the absence of any gold standard with which to measure various technologies [see Appendix 
1], defining their absolute accuracy, sensitivity, and specificity in detecting CTCs remains a 
challenge. 
To address these theoretical challenges, we optimized enrichment system OncoquickTM with 
a multi-antibody assay, named Grab all-assay, with the purpose of identify CTCs with 
epithelial- and mesenchymal/stem- phenotypes.  
The aim of this study was to find and monitor epithelial- and mesenchymal/stem- CTCs to 
investigate them as potential biomarker for the stratification of non-metastatic patients. 
The Grab all-assay compatible with DEPArray system was established to examine tumor cells 
for expression of three pooled Epithelial proteins (EpCAM, E-Cadherin, Cks) [named E-tag] and 
three pooled Mesenchymal/Stem proteins (N-Cadherin, CD44v6, ABCG2) [named MS-tag] as 
well as PBMC marker CD45. 
Grab all-assay was first validated in different cell lines to confirm differential expression in 
epithelial versus mesenchymal cancer cells, and the absence of expression in blood cells that 
usually contaminate CTC preparations (by CD45 marker).  
To do this, we mimicked EMT process by two in vitro models. The first consisted of epithelial 
cell line MCF10A treated by EMT-master-cytokine TGF beta and the second included HME cell 
line overexpressing TFs known as EMT regulators (TWIST1, ZEB-2 and ZEB-1). 
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Different levels of EMT in every cell lines was reflected by different positivity of grab all assay 
tags in both in vitro models. For example, MCF10A naive was positive only for E-tag, whereas 
6-days treated MCF10A tags positivity was reversed (E-tag neg, MS-tag positive). Epithelial 
HMEL was positive only for E-tag, on the contrary forced expression of either TWIST1 or 
ZEB1/2 laid HME cells in an EMT transition state and it was reflected on Grab all assay. 
The recovery capability of our Oncoquick/DEPArray-based method was assessed as previously 
reported 164: a range of 11.6/86% of cell recovery was observed. We next applied 
OncoquickTM/Grab all assay on samples from three healthy blood donors. The specificity of 
Grab all-assay was verified since no false positive CTCs were detected.  
We next analyzed blood samples from 11 patients at various stages of esophageal cancer (4 
metastatic, 7 non-metastatic); blood samplings were achieve before first primary therapy of 
choice (radio-therapy, radio-chemiotherapy, radio-chemiotherapy), one month after therapy 
and, when possible, after surgery.  
Three out of four patients metastatic at diagnosis (M1, M2, M4) were found to be CTC positive 
before primary treatment and died before the end of therapy. This data could prompt to 
describe them as a CTCs-positive-control, because in non-responding metastatic patients CTCs 
could be seeded from every tumor sites (both primary and metastatic lesions). Clinically this 
data albeit on a small population, remind the negative prognostic value of CTCs in metastatic 
cancer 165,166. 
M3 patient with an unanalyzable sample at first blood drawn, resulted positive for 
mesenchymal/stem CTCs during I line chemotherapy.  Concomitant CT outcome indicated a 
partial response at the esophagus lesion but a progression disease in bone lesion. The two 
analyses were conducted during I line chemotherapy probably bringing out that the selected 
therapy didn't had any effect on the bone metastasis. 
Three months later CTCs analysis was still positive. Most of the CTCs were epithelial rather 
than mesenchymal/stem. A simultaneous CT scan indicated an esophagus- and bone- 
stabilization of disease. However, seven months later, the disease still progressed. It possible 
that CTCs status had indicated an early restarting tumor activity not reflected by CT. 
Starting from this hint, we focused on non-metastatic esophageal cancer patients, where 
biologically CTCs are probably gathered only from primary tumor. Hence, a “more linear" 
biological system is probable . 
Recently the group of Leon Terstappen found that, in  early breast cancer setting, pre-surgical 
CTCs detection suggest a higher tumor relapse167. Furthermore CTC detection seems to be a 
stronger indicator of overall and relapse-free survival than pathological LN stage in non-
metastatic esophageal cancer 125.  
Despite the small number of patients, which disallow an accurate statistical analysis, an 
indication of neoadjuvant therapy response would be lead from the comparison of CTC status 
at basal and after therapy.  
One adenocarcinoma patient (NM3) at basal was CTCs positive for both epithelial and 
mesenchymal/stem phenotypes, CTCs status after therapy wasn't executed due to patient 
death. NM3 was the only one patient who died before executing second CTC status. His/her 
esophageal cancer aggressiveness was maybe reflected by mesenchymal/stem CTCs (N-
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cadherin/ABCG2/CD44v6) a similar context was reported in five metastatic breast cancer 
patients 95. 
Three patients affected of adenocarcinoma of the esophagus, with no CTCs at basal, after neo-
adjuvant treatment were found to be positive for CTCs and all of them had a tumor recurrence 
[3-12 months from the end of chemotherapy]. One patient affected of esophageal squamous 
carcinoma had a fluctuating number of CTCs (positive at basal, negative post neo-adjuvant 
treatment, and positive after 4 months from the end of chemotherapy. CT and PET analysis 
indicated a partial response. No surgery was performed due to the occurrence of hepatic and 
lymph nodes metastases concurrent with the last detection of CTCs.  Again, monitoring CTC-
status more than a single sporadic determination could infer more relevant information. 
Noteworthy is the CTC analyses in patients that underwent surgery. Three patients benefited 
from neo-adjuvant treatments as resulted by CT and PET analysis and then they were 
underwent surgery. 
Clinical stage after chemo-radiation (yTNM) indicated 2/3 patients had a T0 stage reflecting 
an actual response to therapy. The third patient resulted T3 stage without tumor regression 
and died one month after surgery. 
Examining CTCs status, the T0 patients were CTCs-negative after neo-adjuvant therapy, in 
particular one was negative even at basal, the other one became CTCs-negative after 
treatment. 
T3 patient was CTCs-negative at basal, but after neo-adjuvant therapy we identified both 
epithelial and mesenchymal/stem CTCs. 
Clinically these results suggest that monitoring CTCs in these cases had traced the actual 
tumor response to therapies even when CT outcome reported a stable disease. Furthermore, 
the presence of CTCs into bloodstream post a neo-adjuvant treatment/pre-surgery could lead 
the possibility of a minimal leukemic-residual cancer. 
Molecular analysis of a cancer related panel of genes on whole genome amplification of CTCs 
are ongoing. Results from these analyses could complete the picture of clinical relevance of 
CTCs highlighted from this study. 
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Appendix 1-  
Techniques for CTC identification  
 
Various approaches have been developed for CTC isolation from blood. Starting with cell line 
models, these technologies were primary developed for obtaining multiple performance 
parameters (i.e. capture efficiency/recovery, enrichment against leukocyte depletion, cell 
viability, processing speed, blood sample capacity) and then validated through testing with 
clinical samples. The optimal isolation approach should require a compromise among 
performance parameters, and the optimal selection is likely to depend on the intended 
downstream application. Table 1 summarizes the most known technologies to isolate CTCs.  
 
TABLE 1  SELECTED TECHNOLOGIES TO ISOLATE CTCS . MODIFIED FROM DOI  10.1038/NRCLINONC .2013.253 
Immuno-affinity systems 
 
Immuno-affinity based CTC isolation takes advantage of highly specific affinity reactions 
between capture antibodies and target antigens present on cells of interest, and are mainly 
sub-grouped in: magnetic beads, microfluidic flow, in vivo sampling, leucocyte depletion. 
MAGNETIC BEADS  
     50 
 
The CellSearch® instrument is the only FDA-cleared technology that is clinically applied for CTC 
enrichment. Its enrichment process involves the binding of antibody functionalized magnetic 
beads to the epithelial cell adhesion molecule (EpCAM) antigen on CTCs, and the subsequent 
isolation of these beads with a magnet. Enumeration of CellSearch®-enriched CTCs has been 
established as a prognostic marker and predictor of patient outcome in metastatic breast 168, 
prostate 169, and colon cancers 170.  Alternative immunomagnetic strategies have also been 
proposed; these similarly rely immuno-targeting of potential CTCs with a magnetic payload 
followed by binding to a magnetic substrate. For example, MACS® (Miltenyi Biotec GmbH, 
Bergisch Gladbach, Germany), or Magnetic Activated Cell Sorting system, is a dedicated 
instrument that captures cells by immunomagnetic labeling with microbeads tagged to 
desiderate target (i.e. anti EpCAM or HER2).  
AdnaTest® (Adnagen AG, Langenhagen, Germany) is a commercialized series of assays that 
employs magnetic beads functionalized with cocktails of antibodies specific to either breast, 
prostate, colon, ovarian or EMT/stem cell markers to improve enrichment. AdnaTest 
BreastCancer™ coupled with multiplexed RT-PCR based CTC detection has been demonstrated 
to correlate with patient outcome in metastatic breast  171 and ovarian cancer 172. The assay 
was also used to identify a subset of CTCs expressing stem cell and EMT markers in primary 
breast cancer 129. In a comparative study AdnaTest BreastCancer™ was positive for 29 of 55 
metastatic breast cancer patients compared with the detection of ≥2 CTCs in 26 of 55 patients 
by CellSearch®173. 
MICROFLUIDIC FLOW  
Nagrath, Toner and colleagues developed a microchip consisting of an array of 78,000 silicon 
micro-pillars functionalized with antibodies targeting EpCAM, allowing the direct processing 
of whole blood, resulting in a capture efficiency of ≥60% and a final sample purity of about 
50% when processing at a throughput of 2.5 mL/hour. This “CTC-chip” was used to enrich and 
identify CTCs in 115 of 116 tested blood samples from patients with various metastatic cancer 
types 140,174,175. To overcome fabrication challenges with the first generation CTC-chip, Stott 
and Toner et al have reported an improved second generation “herringbone chip” that 
promoted microfluidic mixing through the generation of microvortices 140. Here the specific 
capture antibodies were conjugated to the herringbone-shaped grooves along the bottom 
surface of the device, and the flow patterns resulted in increased cell to surface contact. This 
improved capture efficiency to 91.8% using antibodies for EpCAM, and CTCs and microclusters 
were detected in samples from 14 of 15 prostate cancer patients 176. More recently, to 
facilitate the retrieval of CTCs for further analysis, Ozkumur and Toner et al developed a “CTC-
iChip” that enables either positive anti-EpCAM CTC selection or leukocyte depletion after an 
initial size-based enrichment step and hydrodynamic focusing. They reported high capture 
efficiencies of up to 98.6%, with varying purities in the range of 0.02 – 42%. CTCs were 
detected in 37 of 42 metastatic cancer patient samples as compared with 29 of 42 using 
CellSearch® 177. 
IN VIVO SAMPLING  
GILUPI GmbH developed a novel approach for in vivo sampling by functionalizing a medical 
wire with EpCAM antibodies (CellCollectorTM). The medical wire is injected through a cannula 
into the patient’s cubital vein for a duration of 30 minutes to allow direct continuous sampling 
of large volumes of blood (1.5 - 3 liters). This approach successfully enriched CTCs in 22 of 24 
patients diagnosed with either metastatic breast or lung cancer 178. 
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LEUKOCYTE DEPLETION  
An alternate approach to positive immuno-affinity based CTC selection is to use monoclonal 
antibodies targeting leukocyte antigens (i.e., CD45, CD14) to deplete cells of hematopoietic 
origin. Some strategies include antibody labeling of leukocytes for removal through 
immunomagnetic separation 179,180, or through centrifugation with the RosetteSep™ kit 
(StemCell Technologies, Vancouver, Canada) 94,181. These approaches are capable of high 




Physical properties may be exploited to effectively separate CTCs from peripheral blood cells. 
The following technologies have been developed based on differences in density, size, 
deformability and electrical properties. 
DENSITY GRADIENT CENT RIFUGATION  
Centrifugation is a cheap and efficient method for separating CTCs in the mono-nucleocyte 
fraction of blood away from erythrocytes and granulocytes based on cell density. 
Centrifugation with Ficoll-Paque® solution (Pharmacia- Fine Chemicals, Uppsala, Sweden) was 
used to detect CTCs using an RT-PCR based assay for cytokeratin 20 expression with a 
resolution of 1 cell/mL of blood in model systems, successfully identifying CTCs in 24 of 58 
colorectal cancer patients undergoing surgical resection 182. OncoQuick® (Grenier BioOne, 
Frickenhausen, Germany) is a novel technology that incorporates a porous barrier for size-
based separation of CTCs in conjunction with density-based centrifugation. Rosenberg et al 
reported a vastly improved enrichment of 632-fold against leukocytes with OncoQuick® 
compared to 3.8-fold with Ficoll-Paque® 183. OncoQuick® , in addition to the DEPArray 
system158 , has allowed the identification of CTCs in 21 out of of 40 advanced colon cancer 
patients.  
MICROFILTRATION  
Microfiltration operates on the principle of retaining larger CTCs while allowing smaller 
leukocytes to pass through pores of varying geometries. Vona, Paterlini-Brechot, and 
colleagues developed the “isolation by size of epithelial tumor cells” (ISET) technique using 
randomly track-etched polycarbonate filters with 8 μm diameter circular pores for CTC 
enrichment and cytological detection from fixed blood samples 184. Track-etched microfilters 
have been used to enrich and characterize CTCs in studies involving liver cancer 185, melanoma 
186, lung cancer 187,188, prostate cancer 64 and various other cancers 187. These microfilters were 
demonstrated to be more sensitive than CellSearch®, detecting CTCs in 57 of 60 metastatic 
patients with breast, prostate and lung cancer compared to 42 of 60 with CellSearch® 189.  
DIELECTROPHORESIS  
Electrical properties of CTCs may be exploited to discriminate them from blood cells by 
applying a non-uniform electric field through the phenomenon of dielectrophoresis (DEP). 
Interdigitated gold electrodes were used by Becker, Gascoyne, and colleagues to isolate 
leukemia 190 and breast cancer cell lines 190 from spiked healthy donor blood. The application 
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of an electric field generated by the electrodes attracts tumor cells by positive DEP, while 
other cells flow past. Upon removal of the electric field the tumor cells can be collected with 
a capture efficiency of 95% 191. Based on the success of this method, Huang et al proposed a 
DEP field flow fractionation approach to allow continuous processing of samples that did not 
require intermittent application of the electrical field for cell recovery 192. Another use of DEP 
to manipulate single cells or small pools of cell is DEPArray system (Silicon Biosystem).   This 
system is able to work on small populations of cells distinguishing them by 
immunofluorescence and recovering the selected cells performing  cell sorting inside a chip 
where negative DEP cages entrap single cells keeping them floating (see Appendix 2) 
Analytic tools for CTCs 
Various analytic tools have been deployed for the cellular and molecular characterization of 
CTCs (Figure 2). These tools are developed in conjunction with CTC enrichment technologies 
as each downstream application will have its own requirements regarding sensitivity, sample 
purity, cell viability, and ability to recover cells after enrichment. As any CTC isolation and 
analysis process applies certain criteria for enrichment and detection, it is important to 
characterize the false-positive and false-negative rates of the overall CTC process. A common 
practice to establish a new method is to compare results from duplicate samples with the 
CellSearch®, that despite its intrinsic problems is still considered a gold standard in CTCs 
detection 
IMMUNOPHENOTYPING  
Immuno-staining is the current gold standard technique for CTC detection and enumeration 
as established by the FDA-cleared CellSearch® system. The defined criteria for identifying CTCs 
includes (1) positive expression of cytokeratins (CK), a class of intermediate filaments in 
epithelial cells; (2) negative expression of the leukocyte common antigen, CD45; and (3) 
positive staining of the nucleus with DAPI 1. Markers specific to cancer types, such as PSA or 
PSMA in prostate cancer, have also been used for positive CTC identification 176,193,194. 
The lab-on-a-chip based platform, DEPArray, bases the analysis step on immunostaining. 
Compared with  CellSearch system, DEPArray has four/five immunofluorescence channel 
(Veridex has three/four channels). This improvement is useful for testing a more elaborated 
immunophenotyping.  
Recently, attempts have been made to investigate the expression of other proteins to further 
characterize CTCs. The presence of stem cell markers, such as CD44+/CD24−, CD133+, 
ALDH1+, have been identified in CTCs 94,145,171,195,196. Studies attempting to investigate the EMT 
status of CTCs have reported high expression levels of mesenchymal markers such as TWIST, 
AKT2, PIK3α, N-cadherin and vimentin 145,171,188,197. While the direct clinical relevance of such 
markers has yet to be established, they are of significant research interest for better 
characterizing CTCs and understanding their roles in cancer metastasis. 
Human epidermal growth factor receptor 2 (HER2) expression status of breast cancer CTCs 
was determined through IF 198–200. In prostate cancer, CTCs have been assayed for epidermal 
growth factor receptor (EGFR) expression 201, as well as androgen receptor (AR) status 202.  
FLUORESCENCE IN SITU HYBRIDIZATION  
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Somatic alterations to gene copy numbers are a hallmark of many cancers, and can be an 
important prognostic marker. They can further provide valuable predictive information on 
therapeutic efficacy. Meng et al employed a multicolor fluorescence in-situ hybridization 
(FISH) assay on CTCs isolated from breast cancer patients to determine the amplification 
status of the HER2 oncogene 203. They reported some level of non- concordance between 
HER2 status determined by the analysis of primary tumors and with their novel CTC assay. 
Other studies have confirmed this observation with HER2 assays based on IF 199 and RT-PCR 
204. This suggests that a sub- set of patients with initially HER2-negative disease may develop 
HER2-positive CTCs over the course of progression. CTC analysis provides a minimally-invasive 
avenue for repeated screening for the development of genomic aberrations. It is interesting 
to note that CTC HER2 amplification screening has been successfully demonstrated in even 
primary breast cancer patients 205,206. In castration-resistant prostate cancer, multicolor FISH 
has shown potential as a surrogate for status determination of AR and MYC status in CTCs 
after immunomagnetic enrichment with CellSearch® 201,207. 
Oncogenic translocation is an important pathogenic mechanism for some cancers. TMPRSS2-
ERG translocation occurs in 30-70% of therapy-naïve prostate cancer patients 208. Using FISH 
analysis on CTCs, it has been shown that TMPRSS2- ERG fusion can be identified in CTCs of 
prostate cancer patients 176,209. Further, there appears to be a consistency in TMPRSS2-ERG 
translocation between therapy-naïve prostate cancer from core biopsy specimens and from 
CTCs at the time of castration-resistance from the same patients 209. In a recent study using 
FISH, it has been shown that ALK-rearrangement can be identified in non-small cell lung cancer 
patients harboring ALK-translocations 210. 
There is, therefore, much promise through CTC analysis for minimally-invasive tumor profiling 
and improved prognosis related to metastatic disease. However, the low sensitivity of current 
enrichment technologies remains a significant hurdle to routine clinical application. In 
addition, the reliability and clinical relevance of these FISH-based assays must first be 
thoroughly validated. 
ONCOGENE MUTATION DET ECTION AND GENOMIC ANALYSIS  
One of the key attractions for isolating CTCs is to enable the detection of cancer gene 
mutations and genomic aberrations in these metastatic tumor cells that are associated with 
the worst prognosis for survival, reflect drivers of active disease, and predict drug sensitivity 
and resistance. 
Analysis on colon-CTCs analyzed and isolated with DEPArray system, for the first time, 
demonstrated heterogeneity between CTCs and primary tumor tissue on KRAS mutation 158.  
 Using CTCs isolated with microchips, it has been shown that activating EGFR mutations can 
be effectively detected in patients with non-small cell lung cancer using an allele-specific PCR 
amplification technique 175. Further, the EGFR T790M mutation that confers drug resistance 
can also be detected from patients who have received EGFR kinase inhibitor treatment. While 
allele-specific PCR is a fast and cost- effective approach to determine specific mutations, prior 
knowledge of the mutations are necessary for the design of amplicon primer sets. 
With the ability to perform single-cell whole genome amplification, it has been shown that 
one can perform next-generation exome sequencing with CTCs to uncover cancer-specific 
mutations, both pathogenic and passenger, which are present at very different levels of 
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prevalence in primary and metastatic colon cancer 211. Once amplified, the DNA from a single 
CTC can also be used for array-comparative genomic hybridization analysis to uncover 
genomic aberrations, such as large deletions and insertions that cannot be detected with 
exome DNA sequence analysis 211. Although single-cell DNA sequencing is tedious, such 
studies confirm the feasibility of applying CTCs to discovery research in clinical oncology 
studies. Technologies for cancer gene exome analysis such as the Ion Torrent AmpliSeq™ 
Cancer Panels (Life Technologies, Carlsbad, CA) and the TruSeq® Amplicon-Cancer Panel 
(Illumina, San Diego, CA) would facilitate the analysis of cancer mutations in CTCs. 
GENE EXPRESSION ANALYSIS OF CTCS  
While the analysis of mRNA from CTCs presents significant technical challenges due to the 
molecules labile nature, it is desirable due to: (1) specificity to amplicons that are highly 
selectively expressed in tumors but not in white blood cells; (2) the ability to detect gene 
translocations and alternative splice variants; (3) quantitative high-throughput technologies 
such as multiplex digital PCR and expression arrays for cell profiling; (4) potential application 
to next generation sequencing analysis.  
One study on mRNA analysis explains the low abundance of EpCAM expression associated 
with increased vimentin in basal-like breast cancer that is poorly captured with EpCAM- based 
CTC purification schemes212. Another study further demonstrate dynamic changes in epithelial 
and mesenchymal composition in circulating breast cancer cells with mixed probes using RNA 
in situ hybridization, particularly in CTC clusters95. It also suggests a more mesenchymal 
phenotype for the basal-like molecular subtype of breast cancer. Next generation RNA 
sequencing has been performed with CTCs isolated from patients with pancreatic cancer using 
a microfluidic chip 213. RNA sequencing results revealed the activation of WNT signaling in the 
CTCs, which may contribute to tumor metastasis. Taken together, while it is very attractive to 
analyze mRNA for gene expression and pathway profiling, its quantitative analysis requires a 
high quality source of mRNA that is consistently well preserved. 
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Appendix 2-DEPArray System 
The DEPArray systems is a modulary instrument able to manipulate small cell population by 
dielectrophoresis force (DEP). It’s a semi-automatic lab-on-a-chip composed by a 4-
fluorescence (PE, APC, FITC, DAPI) channels optical microscope connected to a camera for the 
computer-analysis and by a device controller for the DEP-manipulation of single cells. 
DIELECTROPHORESIS  
Dielectrophoresis (DEP) is a phenomenon in which a dielectric particle is subjected to a non-
uniform electric field and to an external force.  The particle is polarized by the electric field 
and the resulting poles exert a force along the fields lines, which can be attractive or repulsive 
according to the orientation on the dipole. This non-uniform field leads the greatest electric 
fields to dominate over the other and the particle will move. Due to this characteristic, 
dielectrophoresis can be used to manipulate, separate and sort different type of particles. 
Since biological cells have dielectropforetic properties, dielectrophoresis has many 
medical/research applications. 
DEP forces moving particles towards high intensity voltage areas are named positive DEP 
(pDEP), in the contrary DEP forces moving toward low intensity voltage areas are defined as 
negative DEP (nDEP). In this way, on varying both the shape of electrode and the excitation of 
electric field, the DEP forces can be used to entrap, levitate and manipulate particles 214–216. 
DEP forces could be employed for at least two purpose: first, streaming electrophoresis where 
electrokinesis is dominating and trapping regions immobilizing particles are replaced by 
regions of preferred streaming. Second where DEP act as the dominant force and could be 
used as trapping, here named trapping DEP. [Transitioning Streaming to Trapping in DC 
Insulator-based Dielectrophoresis for Biomolecules] 
CHIP  
As in every Lab-on-a-chip system, the core of the DEPArray system is a disposable cartridge  
(A300K). The A300K is composed by two main parts: a microfluidic system allowing the loading 
of sample and the recovery of the targets; the second part is the active area of 
dielecrophoretic force [Figure 1]. A 640X480 electrodes matrix into the bottom of  the “active 
area” generates the dielectrophoretic cages, whereas on the top a transparent layer is 
exposed to the microscope objectives (for the cellular analysis). The matrix is able to generate 
a maximum of 76*106 nDEP cages. A maximum of 30 thousand cells is permitted to have 1 cell 
per cages (as recommended by the manufacturer).  
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F IGURE 1 DEPARRAY CHIP (A300K). FRONTAL VIEW :  MICROFLUIDIC SYSTEM (A) WHERE THE SYSTEM IS ABLE TO LOAD THE SAMPLE 
THROUGH THE PRESSURE CONTROLLED IN THE VALVES AND TO CARRY THE RECOVERIES IN VOLUMES CHOSEN BY THE OP ERATOR; THE 
ACTIVE AREA OF THE CHIP (B) WHERE SAMPLES ANALYS IS TAKES PLACE. BACK VIEW,  CONTROL VALVES,  ONE FOR THE LOADING THE 
SAMPLE AND ONE FOR THE BUFFER LOADING. 
The microfluidic system is composed by a polycarbonate cover containing different 
microcapillaries for samples loading. Together with sample, a controlled volume of a specific 
buffer must be loaded inside the microfluidic part, this buffer will permit the generation of 
nDEP cages. 
A specific software is designed to control every steps of the calibration, loading, of the 
sample/chip as well as the DEP cages at different conditions (culture media, different buffers). 
The “active area” of the chip is composed by different areas: main chamber, parking  chamber, 
exit chamber each designated for different purpose [Figure 2].  
 
F IGURE 2 ACTIVE AREA OF THE CHIP. THE MAIN CHAMBER IS THE AREA WHERE THE SAMPLE IS LOADED. THE PARKING CHAMBER IS THE 
AREA USED AS A TEMPORARY PARKING PLACE OF THE CELLS READY TO BE RECOVERED; THE EXIT CHAMBER IS THE AREA WHERE THE 
CELLS ARE DIRECTED TO THE SINGLE-CELL RECOVERIES 
The handling of the single cells take place by a pattern of sinusoidal dielectrophoresis [Figure 
3] waves in a  on/off scheme of dielectrophoresis cages leading cells to desired directions. 
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Once A300K cartridge is lodged on the specific support of DEPArray, a series of softwares will 
be lauched, some of them are operator-free other controlled by operator. 
The DEPArray is a platform that allows researchers to decide all the fluorescence settings; 
after choosing the desired setting, “arrangement softwares” perform: calibration of the 
optics, Sample Load, Chip Scan, Cropping of the images. Analysis of the sample is carried by 
the Cell Browser.  
The calibration step basically verify the correct arrangement of the chip inside DEPArray. 
Sample Loading step is composed by three phases: loading of the recovery chamber, parking 
chamber by buffer/culture media then loading of the main chamber with the sample. 
The active area of the chip is scanned by the selected fluorescence channels, in this step 
pictures of every particles is taken (at 10X magnification). The last step, the cropping, is the 
processing of every taken picture in order to edit the entire chip, eliminating for example 
duplicates and assigning to every events an ID number. All these steps are automatic. 
The Cell Browser is the analysis software operator dependant. Software interface is divided 
into analysis panel (where different events visualizations are permitted) and control panel 
where is possible to view cell pictures selected from analysis panel [Figure 4]. Cell Browser 
tools allow the in-detail-analysis and if necessary to take new pictures of the target 
cells/particles with a increased magnification (20x) and different optical settings. 
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F IGURA 4  CELL BROWSER.  THE GRAPHICAL INTERFACE OF THE CELL BROWSER CONSISTS OF ANALYSIS PANEL (A) WHICH LISTS 
ANALYZED EVENTS IN EACH FLUORESCENCES .  CONTROL PANEL (B)  DISPLAYING PHOTOGRAP HS FOR EACH SELECTED EVENT.  BUTTONS 
SHOW EVENTS AS SCATTER PLOTS ,  HISTOGRAMS,  S INGLE EVENT LOCALIZATION INTO THE MAIN CHAMBER AS WELL AS O N BY LISTING 
THEM. THE BUTTON 'CONTINUE'  (D) ALLOWS THE SOFTWARE TO LAUNCH CELL DIRECTOR FOR RECOVERY; PANELS OF THE GALLER IES 
OF IMAGES CAN BE GENERATED (E) AND IT IS POSSIBLE TO RE-CAPTURE IMAGES CHANGING FLUORESCENCE PARAMETERS BY A 20X  
OBJECTIVE (F). 
RECOVERY  
Cell Director software is assigned to sort target cells [Figure 5], operators must interact with a 
graphical user interface which in turn control the active area of the chip. Cell Director designs 
the electric paths across the main chamber that cells must travel to reach parking chamber, 
exit chamber and at last be sorted. “Camera Live” tool enables operators to in-streming view 
step-by-step the route of cells, operators can re-set cells paths in every moments during the 
travel. One into the exit chamber, cells could be recovered singly with 100% of purity by 
leaking a established volume of buffer.     
 
F IGURE 5  CELL DIRECTOR.  GRAPHIC INTERFACE WHERE IT IS  HIGHLIGHTED THE PATHS THAT CELLS  WILL HAVE TO GO THROUGH TO 
REACH THE PARKING CHAMBER (A) AND THE EXIT CHAMBER (B). CAMERA L IVE SOFTWARE ALLOWING TO MONITOR IN-STREAMING 
CELLS MOVEMENTS (C). RECOVERY OF THE CELLS




Detailed clinical histories of esophageal 
cancer patients with CTCs analysis.  
Listed below detailed clinical histories of patients enrolled in this study. 
Red flags indicate CTCs analysis. Where present, hematoxylin and eosin 
stains of patients biopsies were kindly given by Dott. Saragoni of the 
Pathology Unit-Morgagni Pierantoni Hospital , Forlì , Italy.  
CT Computed tomography RP Partial Responce 
PET 
Positron Emission 
Tomography SD Stable Disease 
ETG Echotomography  PD 
Progression 
Disease 
EGDS Esophagoduodenoscopy CP 
Complete 
Response 
TABLE 2  L IST OF ABBREVIATIONS  
 
Shown below detailed clinical histories of patients enrolled on this 
study.
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M1  PATIENT  
 
M2  PATIENT  
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M3  PATIENT  
 
 
M4  PATIENT  
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NM1  PATIENT  
 
NM2  PATIENT  
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NM3  PATIENT  
 













NM5  PATIENT  
 








NM7  PATIENT  
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Appendix-4 Minimal-sample-handling 
protocol for CTC culture- visiting at Prof. 
Vescovi Lab.  
This pilot study of CTC investigation in non-metastatic esophageal cancer patients put forward 
that CTC identification and evaluation at different time points during systemic treatment, as 
a surrogate marker of treatment response as already mentioned in different pathology 168. 
Because CTCs are found in circulation as a collectable fraction that is representative of the 
tumor, they may provide an ideal model to study the biology of the tumor at various intervals 
before and during treatment 217. 
Nonetheless, if CTCs can be isolated from cancer patients as viable cells that can be genotyped 
and functionally characterized over the course of therapy, they have the potential to identify 
treatments that most effectively target the evolving mutational profile of the primary tumor162 
The isolation of viable CTCs is technically challenging: most methods yield low numbers of 
partially purified CTCs that are fixed before isolation, damaged during the cell purification 
process, or irreversibly immobilized on an adherent matrix 162. 
To lay the basis for address this major challenge, together Professor Vescovi Lab under the 
supervision of Elena Binda, we applied a minimal-sample-handling protocol for CTC culture 
from Scid-mouse injected with a colon cancer stem cell line (C12). 
Cancer stem cells are functionally defined as cells that have enhanced tumor-initiating 
capacity upon transplantation into a permissive host 68,69,71,218.  
C12 is a long-term colon cancer stem cell line established in Prof. Vescovi laboratory from a 
surgical specimen of primary colon cancer, growing with a specific serum-free stem cell culture 
medium.  
Due to both the spheroid-like growth of C12 and subculturing procedure by dissociating 
spheres, C12 cell line may bears the self-renewal capacity typical of stem cells 219,220. 
Both subcutaneous xenograft and orthotopic xenograft models determined the in vivo 
tumorigenic potential of C12 cell line. 
C12 cells  tagged with luciferase gene reporter (C12-luc) were subcutaneously injected into 
the right flank of Scid/bg mice as referred 221. After 20/30 days of tumor formation [Fig. 1A], 
mice were sacrificed, tumor sections were stained with hematoxylin and eosin [Fig.1B]. To 
confirm the stemness nature of C12-luc cell line, subcutaneous tumor was dissociated and in 
vitro re-cultured. The generated C12-luc showed the identical growth properties of the 
original C12 derived from patient-tumor [Fig.1C]. The achieving of subsequent generation of 
tumor and in vitro culturing provided the indication that C12 cell line is a bona fide colon 
cancer stem cell. 
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F IGURE 1 C12 CELL LINE STEMNESS V ERIFIED BY SUBCUTANEOUS XENOGRAFT. A REPRESENTATIVE IMAGES OF C12 ENGRAFTED 
SUBCUTANEOUSLY IN SCID-MOUSE.  B HEMATOXYLIN AND EOSIN OF SUBCUTANEOUS TUMOR SECTION .  C C12-LUC CELLS RE-CULTURING 
FROM SUBCUTANEOUS TUMOR,  AFTER 15 DAYS CELLS STARTED TO PROLIFERATE IN THE SAME WAY AS THE STARTING C12  CELLS. 
Orthotopic xenografts bearing C12-luc cells were performed in order to replicate human 
disease with a higher fidelity than subcutaneous xenograft. C12-luc cells were injected on the 
tunica muscularis of the colon at the end of the caecum as by Engleman et al 222; Tumor 
growths were well-visible after 20 days after injection as shown by quantitative imaging of 
luciferase-tagged C12 cells [Fig.2].  
 
F IGURE 2 ORTHOTOPIC XENOGRAFT OF C12 CELL LINE.  TUMOR GROWTH WAS MONI TORED BY QUANTITATIVE IMAGING OF LUCIFERASE-
TAGGED C12  AND QUANTIFIED BASED ON PHOTON FLUX (PHOTONS PER SECOND PER SQUARE CENTIMETER).  AFTER 20 DAYS POST 
TRANSPLANTATION (DPT)  TUMOR MASSES FROM FROM TWO DISTINCT ORTH OTOPIC XENOGRAFTS (OX-A, OX-B) WERE VISIBLE. 
Once verified the stemness status of C12 cell line, a controlled number of C12-luc were 
injected into tail vein of an immunocompromised Scid-mouse. 
3/9x105 C12 cells were injected into tail vein of three Scid-mouse and let them balanced into 
the animals circulation for 3/4 hours. Scid-mice were sacrificed by transcardial perfusion 
(IACUC standard procedure) without fixative solution in order to maintain every cells into the 
blood available for in vitro culturing.  
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After cutting the right atrium, flowing blood was collected until the fluid (PBS1X) exiting from 
the right atrium is entirely clear. 
The resulting blood samples diluted with a solution of PBS 1X-EDTA underwent to the minimal-
sample-handling protocol for CTC culture. 
Briefly, after discarded the plasmatic component from the cellular component we performed 
a gentle erythrocyte lysis until the cell pellets were "colorless". 
Enriched samples were then re-suspended and cultured with a selective  stem cell culture 
medium. 
About ten days after plating, phase-bright clones reflecting the conventional spheres formed 
in vitro by stem-like cells were detected in all of the three cultures established from the three 
injected mice [Fig.3A]. 
Cultured enriched C12 cells shared morphological-growing features with the matched primary 
C12, suggesting that the ability to form sferoids of the putative cancer stem cells was 
preserved.  
Immunofluorescence tests were performed on a small fraction of enriched C12 cells with an 
anti-Luc antibody [Fig.3B] as a formal proof of C12 cell line authentication.  
 
F IGURE 3 CULTURED C12-LUC CELLS FROM WHOLE BLOOD OF TAIL VEIN INJECTED SCID-MICE. A. PHASE-BRIGHT 15  DAYS-CULTURED 
C12-LUC CELL ENRICHED BY MINIMAL-SAMPLE-HANDLING PROTOCOL FOR CTC CULTURE. ENRICHED CELLS GROWTH IN A SPHEROID-LIKE 
FASHION AS THE PARENTAL C12-LUC  B. IMMUNOFLUORESCENCE WI TH ANTI-LUC ANTIBODY (GREEN)  OF 15  DAYS-CULTURED C12-LUC 
CELL AS FORMAL PROOF OF CELLS AUTHENTICATION . DAPI  (BLUE)  COUNTERSTAINED NUCLEUS. 
Traditional CTC isolation technologies are limited by extensive cell loss under relatively harsh 
sample processing conditions that decrease the number and viability of tumor cells circulating 
in the blood.  
During my visiting period at Prof. Vescovi laboratory, we developed a minimal-sample-
handling protocol able to get circulating tumor cells in a proper condition for in vitro culturing. 
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The enrichment of the circulating tumor cells with a stem-growth-competence occurred not 
from the whole blood sample directly, but during the step of cell culture, by culture medium 
selection. 
This new approach minimized both cell lost and cell modifications due to overmuch sample 
handling; it also opens a window on CTCs culture. 
To date orthotopic xenograft model of colon cancer inducted by C12 cell line is ongoing, on 
this model the protocol for culturing CTCs will be employ. As a future perspective, this protocol 
will be applied on whole blood from patients affected by cancer. 
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